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1) Introduction 
1.1) Biogenesis and function of miRNAs 
 
      MicroRNAs (miRNAs) are small molecules consisting of about 22 
nucleotides. Currently, there are 1872 miRNAs annotated according to the 
public microRNA database miRBase (http://www.mirbase.org; Griffiths-Jones, 
2004). miRNAs were initially discovered in the nematode model organism 
Caenorhabditis elegans (Lee et al, 1993) and described as small transcripts 
complementary to a repeated sequence in the 3'-UTR of the lin-14 transcript. 
The authors speculated about an antisense mechanism, which enables these 
small RNAs to regulate the translation of lin-14. Twenty years later this 
hypothesis has been validated by multiple studies elucidating the mode of 
action, which underlies gene regulation by miRNAs. The biogenesis of miRNA 
genes can be sub-divided into two pathways. While in the canonical 
processing pathway the miRNA encoding messenger RNA (mRNA) is 
transcribed from its promoter, so called miRtrons are located in introns of host 
genes, which also encode proteins (Kim et al, 2009; Krol et al, 2010). 
Transcription of miRNA-encoding RNAs is generally executed by RNA 
polymerase II (RNAPol II) resulting in a precursor transcript, the so called 
primary (pri-) miRNA. A protein-complex consisting of dsRNA-binding proteins 
and the RNase III family member Drosha cleaves the pri-miRNA, resulting in 
an approximately 70 nucleotides long precursor hairpin structure, the pre-
miRNA. In case of the miRtrons the pre-miRNA is a result of post-
transcriptional splicing of the host mRNA. The resulting pre-miRNA is trans-
located from the nucleus to the cytoplasm via Exportin-5 (Brownawell & 
Macara, 2002). Once in the cytoplasm, the pre-miRNA is bound by a protein 
complex containing the type III RNase Dicer, which enzymatically cleaves the 
hairpin into two complementary, approximately 22 nucleotides long miRNAs 
bound to each other in a miRNA/miRNA* duplex. Following this processing, 
one or both of the strands are incorporated into the RNA-induced silencing 
complex (RISC), which can target specific mRNA molecules via a mechanism 
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known as RNA interference (Filipowicz, 2005; Sontheimer, 2005; Fire et al, 
1998; Zamore et al, 2000). 
   The minimal RISC complex, sufficient for target recognition and cleavage of 
RNA molecules, also referred to as Slicer, was shown to consist of an 
Argonaute endonuclease protein bound to a small, regulatory, target-
complementary RNA (Rivas et al, 2005; Pratt & MacRae, 2009). The target 
recognition is mediated by binding of an up to seven nucleotides long stretch, 
located within the 5'-portion of the miRNA, the so called seed-sequence, with 
a complementary sequence in the 3'-UTR of the target mRNA, the seed-
matching sequence. This interaction facilitates the recruitment of the 
RISC/Ago2 complex to the targeted mRNA, which results in either inhibition of 
translation initiation, via interfering with the recruitment of the 40S small 
ribosomal subunit, and/or enhancement of mRNA degradation, through 
recruitment of a deadenylase complex, which mediates the removal of the 
poly adenosine tail and subsequent cleavage of the open reading frame 
(ORF; Bartel, 2009; Fabian et al, 2010; Huntzinger & Izaurralde, 2011). 
   The importance of this mechanism for the repression of gene activity is 
universal, since it was found to be phylogenetically conserved in all the 
bilaterally symmetric animals (Pasquinelli et al, 2000). Each miRNA may 
control the expression of hundreds of target mRNAs (reviewed in Bartel, 
2009), and it has been estimated that approximately 60% of all human protein 
coding genes are under influence of miRNA regulation (Friedman et al, 2009). 
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1.2) Epigenetic silencing 
 
   The term epigenetics is defined as heritable changes in gene expression, 
which are not caused by changes of the underlying DNA sequence but by 
chemical modifications of its nucleotides and/or changes in molecules that 
interact with it (Bird, 2007). Epigenetic silencing consequently describes the 
down-regulation of gene expression by epigenetic mechanisms. Recent 
publications suggest that the epigenome is dynamic and reacts in response to 
changes of the environment, diet or aging (Feil & Fraga, 2011; Feinberg, 
2007). The three major mechanisms responsible for these epigenetic changes 
are DNA-methylation, non-coding RNAs, and modifications of histone tails 
(Mulero-Navarro & Esteller, 2008). DNA-methylation occurs by a covalent 
modification, in which a methyl-group is transferred by DNA-
methyltransferases (DNMTs) from S-adenosylmethionine to the C-5 position 
of cytosine, which is located 5’ to a guanosine and forms a CpG dinucleotide 
(Iacobuzio-Donahue, 2009). CpG dinucleotides are under-represented in the 
genome, but in some regions, so called CpG islands, they cluster in high 
density. Often located close to the promoter regions of genes, the CpGs 
within these islands are mainly unmethylated (Jones & Baylin, 2002). 
Methylation of the CpGs negatively influences the expression of gene 
transcription in two ways: First, methyl-CpG-binding domain proteins (MBPs) 
are able to recruit chromatin modifying enzymes like histone-deacetylases 
(HDACs; Jones et al, 1998), which in turn initiate the condensation of 
chromatin and subsequent gene silencing. In cancer this mechanism was first 
discovered for the Retinoblastoma (Rb) tumor suppressor gene about 20 
years ago (Ohtani-Fujita et al, 1993; Sakai et al, 1991). Second, the 
methylation of CpGs might interfere with the binding of transcription factors. 
This results in expression changes as well, as discovered more recently 
(Perini et al, 2005).  
   In total there are more than 100 genes known to be hyper-methylated at the 
promoter in association with cancer (Shames et al, 2007). Recent findings 
indicate that intragenic DNA-methylation exists as well, but the regulatory 
consequences are not well understood so far (Shenker & Flanagan, 2012). 
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Furthermore, there are indications that CpG-methylation is a crucial step in 
the progression from local tumors towards metastases (Li & Chen, 2011). The 
detection of these methylation events is not only important with respect to the 
understanding of underlying mechanisms in tumor initiation and progression, 
but may also serve as biomarker for several different cancer types (Mulero-
Navarro & Esteller, 2008). 
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1.3) The miR-34 family 
 
   The following section introduces members, regulations and cancer-specific 
alterations of this miRNA family.  
 
1.3.1) Members and structure 
 
   The core of the miR-34 family is represented by three members: as shown 
in Figure 1 the miR-34a gene is located on chromosome 1p36 and is 
consisting of two exons connected by a ~30 kbp DNA intron (Hermeking, 
2010). The sequence of the mature miR-34a resides on the second exon. 
miR-34b and miR-34c are encoded by a shared pri-miRNA, which resides on 
chromosome 11q23 and therefore have comparable levels of expression. 
   Due to their high homology in the seed-sequences and secondary 
structures miR-449a/b/c belong to the miR-34 family as well. The respective 
genes are organized as a cluster and embedded into a highly conserved 
intron region of the CDC20B gene on chromosome five (Lize et al, 2011).   
 
1.3.2) Regulation 
 
   In 2007 the miR-34 family acquired wider recognition, since it was found to 
be up-regulated by the tumor suppressor p53, often referred to as ‘guardian of 
the genome’ (Lane, 1992), suggesting an anti-tumor function of this miRNA 
family: several laboratories reported miR-34a to be the most prominently 
induced miRNA upon induction of p53 (Chang et al, 2007; He et al, 2007a; 
Raver-Shapira et al, 2007; Tarasov et al, 2007; Tazawa et al, 2007). As 
shown in Figure 1, one p53 binding site was identified close to the 
transcription start of miR-34a, two additional sites reside upstream of exon 2. 
At the miR-34b/c locus two potential p53 binding sites are located upstream of 
the miRNA genes. Another important regulatory feature, which both loci 
exhibit, is a CpG island. In the miR-34a gene this covers the transcriptional 
start site and the p53 binding site upstream of it (Lodygin et al, 2008). The 
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miR-34b/c promoter harbors a CpG island upstream of exon 2 (Figure 1). As 
described in 1.2 these elements can be hyper-methylated and lead to 
transcriptional silencing of the respective genes. As described in more detail 
in 1.3.3, this is indeed the case for both miR-34 genes.  
 
 
 
 
Figure 1: Structure of genomic loci of the human miR-34a and miR-
34b/c genes. White and black boxes represent exons and miRNA 
hairpins, respectively. Hatched boxes indicate p53-binding sites; CpG 
islands are represented by thick black lines. The model is not shown to 
scale. Chromosomal (Chr) locations of the genes are provided. Figure 
modified from Hermeking, 2010. 
 
   Besides the well documented regulation by p53, other factors regulating 
miR-34 were discovered more recently: While p63, a relative of p53, 
represses miR-34 genes in order to facilitate cell cycle progression, FOXO3a 
was recently shown to induce the expression of miR-34b/c (Antonini et al, 
2010; Kress et al, 2011). Another study reported up-regulation of miR-34a 
mediated by the ETS family transcription factor ELK1 during oncogene 
induced senescence (Christoffersen et al, 2010). Therefore, the miR-34 genes 
are not exclusively regulated by p53. 
   Although closely related to miR-34, the miR-449 family is neither inducible 
by p53 nor by DNA damage. However, a recent publication indicated that 
ectopic expression of miR-449 results in activation of p53 and its downstream 
target p21 as well as the apoptotic markers cleaved Caspase3 and poly 
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(ADP-ribose) polymerase (PARP; Bou Kheir et al, 2011). Moreover, the 
authors found that miR-449 expression is down-regulated in gastric cancer. 
The role of miR-449 in apoptosis was further confirmed by another group 
suggesting a tumor suppressive function of miR-449 (Lize et al, 2010). Since 
its expression is up-regulated by the transcription factor E2F1, it is 
conceivable that miR-449 is a component of a failsafe mechanism against 
uncontrolled proliferation (Lize et al, 2010; Yang et al, 2009). 
 
1.3.3) Role in cancer and aberrations  
 
   As depicted in Figure 2, the miR-34 family has been linked to multiple tumor 
suppressive effects of p53, among them induction of apoptosis, cell cycle 
arrest and senescence (He et al, 2007b; Hermeking, 2012). Several cancer 
relevant molecules can be targeted on the mRNA level by miR-34 like for 
instance the survival factor Bcl-2, different cyclin-dependent kinases (CDKs) 
or CD44, which may mediate the effects mentioned above (Bommer et al, 
2007; He et al, 2007a; Liu et al, 2011). Other miR-34-targeted mRNAs encode 
proteins playing crucial roles in the formation and/or progression of cancer as 
well and are distributed over many functional classes of proteins: cell surface 
receptor molecules like c-Met, Axl, PDGF receptor and Notch (Bae et al, 
2012; Li et al, 2009; Mudduluru et al, 2011; Silber et al, 2012), as well as 
transcription factors like Myc and SMAD (Christoffersen et al, 2010; 
Genovese et al, 2012) and regulatory elements like LEF1, MTA2 and SATB2 
(Kaller et al, 2011; Wei et al, 2012) or kinase components of signaling 
cascades like MEK1 (Ichimura et al, 2010) are targeted. This diversity of 
targets makes the miR-34 family the ‘extended arm of p53’, which amplifies 
the inhibitory effect of p53 on various processes in malignant cells.  
   In line with its crucial role in tumor suppression, the miR-34 family was 
found to be down-regulated in different types of cancer by several 
mechanisms. Most frequently, methylation-dependent down-regulation of 
miR-34a was found in multiple types of cancer, among them colorectal, 
prostate, ovarian, pancreatic, esophageal, breast, renal cell and urothelial 
cancer as well as melanomas, soft tissue sarcomas and hematological 
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malignancies (Chen et al, 2012; Chim et al, 2010; Corney et al, 2010; Lodygin 
et al, 2008; Vogt et al, 2011). Methylation of miR-34b/c was found in 
colorectal, gastric, lung, ovarian, pancreatic, esophageal, breast, renal cell 
and urothelial cancer as well as soft tissue sarcomas (Chen et al, 2012; 
Corney et al, 2010; Suzuki et al, 2010; Toyota et al, 2008; Vogt et al, 2011; 
Wang et al, 2011). In addition, deletion of the miR-34 gene loci was reported 
in colorectal cancer (Lee et al, 2000; Thorstensen et al, 2000). 
   Another, more cancer-specific alteration, which affects miRNA expression, 
is the loss or dysregulation of components of the miRNA processing 
machinery. Loss of Dicer1 and Drosha or mutations of TARBP2 or XPO5 lead 
to a global down-regulation of miRNAs (Lujambio & Lowe, 2012). This was 
shown to be associated with enhanced tumorigenic capacity in different 
cancer types (Melo & Esteller, 2011). One could assume that the loss of miR-
34 expression contributes to this effect.  
   Besides tumor suppression miR-34 is known to be involved in other 
physiological processes such as bone development , cardiovascular diseases 
and aging (Bae et al, 2012; Bernardo et al, 2012; Boon et al, 2013; Li et al, 
2011; Maes et al, 2009; Xu et al, 2012). Moreover, decreased miR-34 
expression is associated with asthma and T cell recruitment (Solberg et al, 
2012; Yang et al, 2012a).  
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Figure 2: The miR-34 family amplifies the p53-mediated response 
upon cellular stresses by targeting a versatile portfolio of mRNAs. 
(1) Several different cellular stresses (shown in red) converge in an 
induction/activation of p53 (black). (2) p53 in turn induces transcription of 
the miR-34 family. (3) The miR-34 family amplif ies the p53 response by 
targeting multiple mRNAs (some examples are shown in grey) involved in 
a multitude of processes. (4) Repression of miR-34 targets triggers 
several protective processes (dark blue) in response to cellular stress. 
Figure adapted to Hermeking, 2007.  
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1.4) Epithelial to mesenchymal transition in cancer progression 
and metastases 
 
   The term ‘epithelial to mesenchymal transition’ or short EMT describes a 
reversible process, initially observed in developmental biology, in which cells 
lose their epithelial nature and become more migratory, or in the context of 
cancer, more invasive (Sanchez-Tillo et al, 2012; Thiery et al, 2009). Besides 
that, cells undergoing EMT have been shown to acquire characteristics of 
cancer stem cells (CSCs) like for example self-renewal (Thiery et al, 2009).  
This is essential for cancer cells to metastasize from the primary tumor 
throughout the body (Mani et al, 2008; Polyak & Weinberg, 2009). The EMT 
process is characterized by expression changes of several molecular 
markers: cells undergoing EMT for instance express low levels of the 
adhesion molecule E-cadherin, while the mesenchymal-specific intermediate 
filament Vimentin and/or the extracellular-matrix-glycoprotein Fibronectin are 
expressed at elevated levels (Perl et al, 1998; Nieto, 2011). In the recent 
years several EMT-triggering transcription factors (EMT-TFs) could be 
identified, among them ZEB1 and 2, Snail (SNAI1) and Slug (SNAI2), which 
mediate these changes (Batlle et al, 2000; Eger et al, 2005; Thiery et al, 
2009). A common structural feature of these EMT-TFs is a zinc-finger DNA 
binding domain, which mediates the direct binding to so called enhancer (E)-
box recognition sites in the promoters of EMT effectors as for instance E-
cadherin (Giroldi et al, 1997).  
   EMT-TFs were found to be up-regulated in a variety of solid tumor types 
such as breast, head and neck, ovarian and colorectal cancer (CRC; Thiery et 
al, 2009; Roy et al, 2005). Once arrived at metastatic sites, the invasive cells 
need to re-seed and grow out in order to form a solid tumor, which requires 
the reversal of EMT in a process called mesenchymal to epithelial transition or 
MET (Nieto, 2011). 
   Initial results obtained in our group showed that one of the EMT-TFs, 
namely Snail, was repressed upon DNA damage in a p53 and miR-34a-
dependent manner and represents a direct miR-34 target. The functional 
characterization of this regulatory connection was part of this thesis. 
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1.5) c-Kit and the stem cell factor signaling  
 
   The type III receptor tyrosine kinase (RTK) c-Kit (also known as CD117 or 
stem cell factor receptor) is a central component of several signaling 
cascades. It was initially identified as the cellular homologue of the viral 
oncogene v-Kit encoded by the Hardy-Zuckerman 4 feline sarcoma virus 
(Besmer et al, 1986; Yarden et al, 1987). Binding of its ligand stem cell factor 
(SCF), also known as steel factor, leads to homo-dimerization and auto-
phosphorylation of specific tyrosine residues on the intracellular domain of the 
c-Kit receptor and thereby results in stimulation of different pathways 
(Anderson et al, 1990). Among these are the PI-3, Src, Jak/Stat and MAP 
kinase pathways as well as Phospholipase C and D signaling (Lennartsson & 
Ronnstrand, 2012). Under physiologic conditions c-Kit is involved in 
hematopoiesis, pigmentation, gametogenesis, T cell differentiation and mast 
cell regulation (Galli et al, 1994; Kitamura et al, 1995; Krishnamoorthy et al, 
2008; Lennartsson & Ronnstrand, 2012; Rothschild et al, 2003). However, 
elevated expression and mutational activation of c-Kit can cause several 
types of diseases among them cancer (Lennartsson & Ronnstrand, 2012).  
   The c-Kit signaling axis is therefore involved in different types of 
malignancies, such as acute myeloblastic leukemia (Ikeda et al, 1991; Wang 
et al, 1989), glioblastoma (Mahzouni & Jafari, 2012), melanoma (Montone et 
al, 1997; Natali et al, 1992), as well as lung (Hida et al, 1994; Krystal et al, 
1996) and breast cancer (Hines et al, 1995). Aberrant activation of c-Kit is 
associated with chemoresistance of cancer cells, increased oncogenic 
signaling, e.g. in gastrointestinal stromal tumors (GISTs), and mediates 
escape from apoptotic triggers and increases invasive potential  (Bellone et al, 
2001; Duensing et al, 2004; Catalano et al, 2004; Luo et al, 2011; Chau et al, 
2012). Expression of the c-Kit ligand SCF is often elevated in cancer as well 
and contributes to the autocrine/paracrine transmission of oncogenic signals 
(Bellone et al, 2006; Hibi et al, 1991; Martinho et al, 2008; Theou-Anton et al, 
2006). Taken together, the c-Kit/SCF axis seems to play a central role in 
different types of malignancies.  
Introduction 
 
12 
 
   Interestingly, several miRNAs have been described to down-regulate c-Kit 
mRNA among them miR-193a, 193b, 221, 222 and 494 (Felli et al, 2005; Gao 
et al, 2011a; Gao et al, 2011b; Kim et al, 2011e). Additionally, a recent study 
revealed a p53-dependent down-regulation of c-Kit in mice (Abbas et al, 
2011). However, direct binding of p53 to the c-Kit promoter was not detected 
within 5 kbp upstream of the transcriptional start site (TSS). As mentioned 
above, p53 is an important tumor suppressor and amplifies the response to 
cellular stress by activation of target genes as the members of the miR-34 
family (He et al, 2007a; Raver-Shapira et al, 2007; Tarasov et al, 2007). 
Based on these findings, we hypothesized that a p53-mediated up-regulation 
of miR-34, which might target the mRNA of c-Kit, would result in a decrease of 
c-Kit protein expression and function after DNA damage. The validation and 
functional characterization of a putative p53/miR-34/c-Kit axis was another 
topic of this thesis.  
Aims of the thesis 
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2) Aims of the thesis 
 
 
 
 
The present study had the following aims: 
 
 
 
I)  Functional characterization of Snail as a miR-34a target 
 
 
II) Detection and evaluation of miR-34a CpG-methylation and expression 
in combination with the detection of target expression as prognostic 
markers for distant metastases in colon cancer 
 
 
III) Characterization of c-Kit as a new miR-34 target and the resulting 
consequences in cancer cells   
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3) Materials 
3.1) Chemicals and reagents 
 
Compound Supplier 
5-FU (5-fluorouracil) Sigma-Aldrich, St. Louis, MD, USA 
Ampicillin Sigma-Aldrich, St. Louis, MD, USA 
APS (ammonium peroxodisulfate) Carl Roth GmbH, Karlsruhe, Germany 
BD Matrigel™ Basement Membrane Matrix BD Bioscience, Heidelberg, Germany 
Christal violet Carl Roth GmbH, Karlsruhe, Germany 
Complete mini protease inhibitor cocktail Roche Diagnostics GmbH, Mannheim, Germany 
DAPI (2-(4-amidinophenyl)-6-indolecarbamidine 
dihydrochloride) 
Carl Roth GmbH, Karlsruhe, Germany 
dNTPs (deoxynucleotides triphosphate) Thermo Fisher Scientific Inc., Waltham, MA, USA 
DMEM Life Technologies GmbH, Darmstadt, Germany 
DMSO (dimethyl-sulfoxide) Carl Roth GmbH, Karlsruhe, Germany 
Doxorubicin Sigma-Aldrich, St. Louis, MD, USA 
Doxycycline hyclate Sigma-Aldrich, St. Louis, MD, USA 
ECL/HRP substrate Immobilon, Merck Millipore, Billerica, MA, USA 
Ethidium bromide Carl Roth GmbH, Karlsruhe, Germany 
Fast SYBR® Green Master Mix Applied Biosystems, Foster City, CA, USA 
FBS (fetal bovine serum) 
Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
FuGENE®6 Transfection Reagent Promega, Madison, WI, USA 
Gene Ruler 100bp plus DNA ladder Fermentas GmbH, St. Leon-Rot, Germany 
Gene Ruler Low Range DNA ladder Fermentas GmbH, St. Leon-Rot, Germany 
Hi-Di™ Formamide Applied Biosystems, Foster City, CA, USA 
HiPerFect Transfection Reagent Qiagen GmbH, Hilden, Germany 
Hygromycin B Invitrogen GmbH, Karlsruhe, Germany 
Immobilon-P Transfer Membrane Immobilon, Merck Millipore, Billerica, MA, USA 
LB agar (Lennox) Carl Roth GmbH, Karlsruhe, Germany 
LB medium (Luria/Miller) Carl Roth GmbH, Karlsruhe, Germany 
Lipofectamine™ 2000 Invitrogen GmbH, Karlsruhe, Germany 
Mc Coy’s medium Life Technologies GmbH, Darmstadt, Germany 
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Compound Supplier 
Methyl cellulose Sigma-Aldrich, St. Louis, MD, USA 
Mitomycin C  Sigma-Aldrich, St. Louis, MD, USA 
Nonidet®P40 Substitute Sigma-Aldrich, St. Louis, MD, USA 
O’Gene Ruler 1kb DNA ladder Fermentas GmbH, St. Leon-Rot, Germany 
Opti-MEM® Life Technologies GmbH, Darmstadt, Germany 
PageRuler™ Prestained Protein Ladder Fermentas GmbH, St. Leon-Rot, Germany 
Paraformaldehyde Merck KGaA, Darmstadt, Germany 
peqGOLD Universal Agarose  
PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
Phenol /C/I for RNA extraction Promega GmbH, Mannheim, Germany 
PhosSTOP Phosphatase Inhibitor Cocktail Roche Diagnostics GmbH, Mannheim, Germany  
PolyHEMA (poly(2-hydroxyethyl methacrylate)  Sigma-Aldrich, St. Louis, MD, USA 
ProLong Gold Antifade  Invitrogen GmbH, Karlsruhe, Germany 
Propidium iodide Sigma-Aldrich, St. Louis, MD, USA 
Puromycin dihydrochloride Sigma-Aldrich, St. Louis, MD, USA 
Rotiphorese Gel 30 (37,5:1) Carl Roth GmbH, Karlsruhe, Germany 
RPMI 1640 medium Life Technologies GmbH, Darmstadt, Germany 
SCF  (stem cell factor), human recombinant ImmunoTools, Friesoythe, Germany 
SDS (sodium dodecyl sulfate) Carl Roth GmbH, Karlsruhe, Germany 
Sea Plaque® Agarose Lonza Ltd., Basel, Switzerland 
Skim milk powder Fluka, Sigma-Aldrich, St. Louis, MD, USA 
Temed (tetramethylethylendiamin,1,2-bis 
(dimethylamino) -ethan) 
Carl Roth GmbH, Karlsruhe, Germany 
Triton X 100 Carl Roth GmbH, Karlsruhe, Germany 
Trypsin-neutralization solution  Lonza Ltd., Basel, Switzerland 
Tween® 20 Sigma-Aldrich, St. Louis, MD, USA 
Water (molecular biological grade) 
Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
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3.2) Enzymes 
 
Enzyme Supplier 
DNAse I (RNAse-free) Sigma-Aldrich, St. Louis, MD, USA 
FIREPol® DNA Polymerase Solis BioDyne, Tartu, Estonia 
Platinum® Taq DNA polymerase Invitrogen GmbH, Karlsruhe, Germany 
Proteinase K Sigma-Aldrich, St. Louis, MD, USA 
Restriction endonucleases New England Biolabs GmbH, Frankfurt, Germany 
RNAse A Sigma-Aldrich, St. Louis, MD, USA 
T4 DNA ligase Thermo Fisher Scientific Inc., Waltham, MA, USA 
Trypsin (10×, phenol-red free) Invitrogen GmbH, Karlsruhe, Germany 
 
 
3.3) Kits 
 
Kit Supplier 
BCA Protein Assay Kit  
Pierce, Thermo Fisher Scientific, Inc., Waltham, 
MA, USA 
BigDye® Terminator v3.1 Cycle Sequencing Kit  Life Technologies GmbH, Darmstadt, Germany 
DNeasy® Blood&Tissue Kit QIAGEN GmbH, Hilden, Germany 
DyeEx® 2.0 Spin Kit QIAGEN GmbH, Hilden, Germany 
EZ DNA Methylation Kit 
Zymo Research Europe GmbH, Freiburg, 
Germany 
High Pure miRNA Isolation Kit Roche Diagnostics GmbH, Mannheim, Germany 
High Pure RNA Isolation Kit Roche Diagnostics GmbH, Mannheim, Germany 
Pure Yield™ Plasmid Midiprep System Promega GmbH, Mannheim, Germany 
QIAamp DNA Micro Kit QIAGEN GmbH, Hilden, Germany 
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Kit Supplier 
QIAprep Spin Miniprep Kit QIAGEN GmbH, Hilden, Germany 
QIAquick Gel Extraction Kit QIAGEN GmbH, Hilden, Germany 
QuikChange II XL Site-Directed Mutagenesis Kit 
Stratagene, Agilent Technologies GmbH & Co.KG, 
Waldbronn, Germany 
TaqMan® MicroRNA Reverse Transcription Kit 
Applied Biosystems, Life Technologies GmbH, 
Darmstadt, Germany 
TaqMan® qPCR Detection Kit 
Applied Biosystems, Life Technologies GmbH, 
Darmstadt, Germany 
Verso cDNA Kit Thermo Fisher Scientific Inc., Waltham, MA, USA 
 
3.4) Antibodies 
3.4.1) Primary antibodies 
 
Antigen Source/Clone Application Supplier/Clone 
-tubulin Mouse/ DM 1A WB Sigma-Aldrich, St. Louis, MD, USA 
β-catenin Mouse/ clone 14 IHC 
Ventana Medical Systems, Oro Valley, 
AZ, USA 
β-catenin Mouse WB BD PharMingen, Heidelberg, Germany 
β-catenin Rabbit IF Epitomics, Burlingame, CA, USA 
c-Kit Rabbit WB 
Dako Deutschland GmbH, Hamburg, 
Germany 
c-Met Rabbit/ EP1454Y IHC Epitomics, Burlingame, CA, USA 
E-cadherin Mouse/ 4A2C7 WB, IF Invitrogen GmbH, Karlsruhe, Germany 
Erk Rabbit WB 
Cell Signaling Technology, Inc., Danvers, 
MA, USA 
p-Erk Rabbit WB 
Cell Signaling Technology, Inc., Danvers, 
MA, USA 
HDAC1 Rabbit WB Epitomics, Burlingame, CA, USA 
p53 Mouse/ DO-1 WB 
Santa Cruz Biotechnology, Inc., 
Heidelberg 
p53 Mouse/ DO-7 IHC 
Thermo Scientific, Lab Vision 
Corporation, Freemont, CA, USA 
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Antigen Source/Clone Application Supplier/Clone 
Slug Rabbit/ H-140 WB 
Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany 
Snail Rabbit WB, IF 
Cell Signaling Technology, Inc., Danvers, 
MA, USA 
Snail Rabbit IHC Acris Antibodies, San Diego, CA, USA 
VSV Rabbit WB, IF Sigma-Aldrich, St. Louis, MD, USA 
Vimentin Rabbit/ EPA3776 WB, IF Epitomics, Burlingame, CA, USA 
ZEB1 Rabbit/ H-102 WB, ChIP 
Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany 
ZEB2 Mouse/ E-11 WB 
Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany 
 
WB: Western blot analysis, IF: immunofluorescence, ChIP: chromatin immuno-
precipitation, IHC: immunohistochemistry   
 
3.4.2) Secondary antibodies 
 
Name Source/Clone Application Supplier 
Anti-Mouse HRP Goat WB 
Promega GmbH, 
Mannheim, Germany 
Anti-Mouse-Alexa 
Fluor-555 
Goat IF 
Invitrogen GmbH, 
Karlsruhe, Germany 
Anti-Rabbit HRP Goat WB 
Sigma-Aldrich, St. Louis, 
MD, USA 
Anti-Rabbit-Cy3 Donkey IF 
Jackson Immuno-
Research Europe Ltd., 
Newmarket, Suffolk, UK 
Phalloidin-Alexa-647 - IF 
Invitrogen GmbH, 
Karlsruhe, Germany 
 
WB: Western blot analysis, IF: immunofluorescence 
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3.5) DNA constructs and oligonucleotides 
3.5.1) Vectors 
 
Name Insert Reference 
pRTR  Jackstadt et al, 2013 
pRTR-p53 human p53  
pRTR-miR-34a human miR-34a Kaller et al, 2011 
pRTR-Snail human Snail   
pRTR-c-Kit human c-Kit   
pRTS-c-Kit human c-Kit   
tTA-p53 human p53 Yu et al, 1999 
pGL3-control-MCS  Welch et al, 2007 
pGL3-Snail wt human Snail 3'UTR  
pGL3-Snail mut human Snail 3'UTR  
pGL3-c-Kit human c-Kit 3'UTR  
pGL3-c-Kit mut1 human c-Kit 3'UTR  
pGL3-c-Kit mut2 human c-Kit 3'UTR  
pGL3-c-Kit mut1 + 2 human c-Kit 3'UTR  
pRL Renilla Pillai et al, 2005 
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3.5.2) Primers 
 
Name Sequence (5’ – 3’) Purpose REF 
AchR fwd CCTTCATTGGGATCACCACG qChIP  
AchR rev AGGAGATGAGTACCAGCAGGTTG qChIP  
β-actin fwd TGACATTAAGGAGAAGCTGTGCTAC qPCR  
β-actin rev GAGTTGAAGGTAGTTTCGTGGATG qPCR  
β-catenin fwd AGCTGACCAGCTCTCTCTTCA qPCR  
β-catenin rev CCAATATCAAGTCCAAGATCAGC qPCR  
BMI-1 fwd TTCTTTGACCAGAACAGATTGG qPCR  
BMI-1 rev GCATCACAGTCATTGCTGCT qPCR  
CD133 fwd TCCACAGAAATTACCTACATTGG qPCR Horst et al, 2009 
CD133 rev CAGCAGAGAGCAGATGACCA qPCR Horst et al, 2009 
CD44 fwd GCCTACTGCAAATCCAAACAC qPCR  
CD44 rev GAAGCTCTGAGAATTACTCTGCTG qPCR  
CDH1 fwd CCCGGGACAACGTTTATTAC qPCR 
Lindner et al, 
2010 
CDH1 rev GCTGGCTCAAGTCAAAGTCC qPCR 
Lindner et al, 
2010 
c-Fos fwd AGAATCCGAAGGGAAGGAA qPCR  
c-Fos rev ATCAAGGGAAGCCACAGACA qPCR  
c-Kit 34a site1mut fwd 
CCCACAGGAGTGGGAAAACAGTCGGATCTTAGT
TTGGATTCT 
mutagenesis  
c-Kit 34a site1mut rev 
AGAATCCAAACTAAGATCCGACTGTTTTCCCACT
CCTGTGGG 
mutagenesis  
c-Kit 34a site2mut fwd 
ACTCCCCTTCCTCAGTCGGCAATATAAAAGGCAA
ATGTGTAC 
mutagenesis  
c-Kit 34a site2mut rev 
GTACACATTTGCCTTTTATATTGCCGACTGAGGA
AGGGGAGT 
mutagenesis  
c-Kit fwd CAGGCAACGTTGACTATCAGT qPCR Li et al, 2007 
c-Kit rev ATTCTCAGACTTGGGATAATC qPCR Li et al, 2007 
GAPDH fwd GCTCTCTGCTCCTCCTGTTC qPCR  
GAPDH rev ACGACCAAATCCGTTGACTC qPCR  
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Name Sequence (5’ – 3’) Purpose REF 
hsa c-Kit 3'UTR fwd ACCCTGGCATTATGTCCACT Cloning  
hsa c-Kit 3'UTR rev GGGAATATTCAAAAGACATTATTGC Cloning  
Lgr5 fwd GCATTTGGAGTGTGTGAGAA qPCR  
Lgr5 rev AGGGCTTTCAGGTCTTCCTC qPCR  
miR-34a M fwd GGTTTTGGGTAGGCGCGTTTC MSP 
Lodygin et al, 
2008 
miR-34a M rev TCCTCATCCCCTTCACCGCCG MSP 
Lodygin et al, 
2008 
miR-34a qChIP fwd TTTTCAGGTGGAGGAGATGC qChIP  
miR-34a qChIP rev AGGACTCCCGCAAATCTC qChIP  
miR-34a U fwd IIGGTTTTGGGTAGGTGTGTTTT MSP 
Lodygin et al, 
2008 
miR-34a U rev AATCCTCATCCCCTTCACCACCA MSP 
Lodygin et al, 
2008 
miR-34b/c M fwd TTTAGTTACGCGTGTTGTGC MSP 
Toyota et al, 
2008 
miR-34b/c M rev ACTACAACTCCCGAACGATC MSP 
Toyota et al, 
2008 
miR-34b/c site1 fwd CGCTGGCAGTTCATTTTAGC qChIP  
miR-34b/c site1 rev TCAATTCAGTGCCTTTGAAGAA qChIP  
miR-34b/c site2 fwd GCCAAAGCTAAAGCAGAAGGTA qChIP  
miR-34b/c site2 rev TCAGGAGAGACAAGGTTGATGA qChIP  
miR-34b/c U fwd TGGTTTAGTTATGTGTGTTGTGT MSP 
Toyota et al, 
2008 
miR-34b/c U rev CAACTACAACTCCCAAACAATCC MSP 
Toyota et al, 
2008 
Nanog fwd ATGCCTCACACGGAGACTGT qPCR  
Nanog rev AGGGCTGTCCTGAATAAGCA qPCR  
NanogP8 fwd TCCATCCTTGCAAATGTCTTC qPCR  
NanogP8 rev AGGGCTGTCCTGAATAAGCA qPCR  
OLFM4 fwd TGGTCATACAGCTGAAGGAGAGT qPCR  
OLFM4 rev GCTTCTCTACCAAGAGAGTCATATTTC qPCR  
Oncostatin M fwd CACACAGAGGACGCTGCTCA qPCR 
Hoermann et al, 
2011 
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Name Sequence (5’ – 3’) Purpose REF 
Oncostatin M rev ATGCTCGCCATGCTTGGAA qPCR 
Hoermann et al, 
2011 
pri-miR-200b fwd CGCAGCAGTGGAACCTGT qPCR  
pri-miR-200b rev GTGAGGAGGTGCTGGGATG qPCR  
pri-miR-200c fwd CTTAAAGCCCCTTCGTCTCC qPCR  
pri-miR-200c rev AGGGGTGAAGGTCAGAGGTT qPCR  
pri-miR-34a fwd CGTCACCTCTTAGGCTTGGA qPCR 
Lodygin et al, 
2008 
pri-miR-34a rev CATTGGTGTCGTTGTGCTCT qPCR 
Lodygin et al, 
2008 
pri-miR-34b/c fwd GAGCTGCCTGTGCATCATC qPCR  
pri-miR-34b/c rev GGATGAAATCAGCATTTTCCA qPCR  
Snail fwd GCACATCCGAAGCCACAC qPCR  
Snail rev GGAGAAGGTCCGAGCACA qPCR  
Sox2 fwd TGCGAGCGCTGCACAT qPCR  
Sox2 rev TCATGAGCGTCTTGGTTTTCC qPCR  
SP6 Promoter TATTTAGGTGACACTATAG (colony) PCR  
T7 Promoter TAATACGACTCACTATAGGG (colony) PCR  
Vimentin fwd TACAGGAAGCTGCTGGAAGG qPCR  
Vimentin rev ACCAGAGGGAGTGAATCCAG qPCR  
 
REF = reference, fwd = forward, rev = reverse, PCR = polymerase chain reaction, 
qPCR = quantitative (real time) PCR, qChIP = fast Chromatin immuno precipitation, 
MSP = methylation specific PCR, I = Inosine  
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3.5.3) MicroRNA mimics and antagomiRs 
 
   The following pre-miRNA mimics and antagomiRs were purchased from 
Ambion GmbH, Kaufungen, Germany: 
 
 pre-miR-control 
 pre-miR-34a 
 pre-miR-34b 
 pre-miR-34c 
 anti-miR-control 
 anti-miR-34a 
 
3.6) Buffers and solutions 
 
Propidium iodide staining solution: 
 
 800 µl propidium iodide (1.5 mg/ml) 
 1000 µl RNAse A (10 mg/ml) 
 ad 20 ml PBS 0.1% Triton X. 
 
Mini Prep buffer1 (MP1): 
 
 50 mM Tris-HCl (pH 8) 
 10 mM EDTA 
 100 µg/ml RNAse A 
 
Mini Prep buffer2 (MP2): 
 
 200 mM NaOH 
 1% SDS 
 
Mini Prep buffer3 (MP3): 
 
 3 M potassium acetate 
 pH 5.5 
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10x ‚Vogelstein‘ PCR buffer: 
 
 166 mM NH4SO4     
 670 mM Tris (pH 8.8)     
 67 mM MgCl2     
 100 mM -mercaptoethanol   
 
RIPA buffer (for protein lysates): 
 
 1% NP40 
 0.5% sodium deoxycholate 
 0.1% SDS 
 NaCl 150 mM 
 50 mM TrisHCl (pH 8.0)  
 
2xLaemmli buffer: 
 
 125 mM TrisHCl (pH 6.8) 
 4% SDS 
 20% glycerol 
 0.05% bromophenol blue (in H2O)  
 10% -mercaptoethanol [added right before use] 
 
10xTris-glycine-SDS running buffer (5l, for protein gels): 
 
 720 g glycine  
 150 g Tris base  
 50 g SDS  
 pH 8.3-8.7 
 ad 5 liters ddH2O 
 
Towbin buffer (for protein blotting): 
 
 200 mM glycine 
 20% methanol 
 25 mM Tris base (pH 8.6) 
 
10xTBST (5l): 
 
 500 ml 1M Tris (pH 8.0)  
 438.3 g NaCl  
 50 ml Tween20  
 ad 5 liters ddH2O 
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3.7) Laboratory equipment 
 
Device Supplier 
5417C table-top centrifuge  Eppendorf AG, Hamburg, Germany 
ABI 3130 genetic analyzer capillary sequencer Applied Biosystems, Foster City, USA 
Axiovert 25 microscope  Carl Zeiss GmbH, Oberkochen, Germany 
BD Accuri
TM 
C6 Flow Cytometer Instrument Accuri, Erembodegem, Belgium 
Biofuge fresco Heraeus; Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Biofuge pico table top centrifuge Heraeus; Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Boyden chamber transwell membranes  
(pore size 8.0 µm)  
Corning Inc., Corning, NY, USA 
CF40 Imager  Kodak, Rochester, New York, USA 
Falcons, dishes and cell culture materials Schubert & Weiss OMNILAB GmbH & Co. KG 
Fisherbrand FT-20E/365 transilluminator Fisher Scientific GmbH, Schwerte, Germany 
Forma scientific CO2 water jacketed incubator Thermo Fisher Scientific, Inc., Waltham, MA, USA 
GeneAmp® PCR System 9700  Applied Biosystems, Foster City, USA 
Herasafe KS class II safety cabinet Thermo Fisher Scientific, Inc., Waltham, MA, USA 
HTU SONI130  
G. Heinemann Ultraschall- und Labortechnik, Schwäbisch 
Gmünd, Germany 
ME2CNT membrane pump Vacuubrand GmbH & CO KG, Wertheim, Germany 
Megafuge 1.0R Heraeus; Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Mini-PROTEAN®-electrophoresis system Bio-Rad, München, Germany 
MultiImage Light Cabinet  Alpha Innotech, Johannesburg, South Africa 
ND 1000 NanoDrop Spectrophotometer NanoDrop products, Wilmington, DE, USA 
Neubauer counting chamber  Carl Roth GmbH & Co, Karlsruhe, Germany 
Orion II luminometer 
Berthold Technologies GmbH & Co. KG, Bad Wildbad, 
Germany 
PerfectBlue™ SEDEC 'Semi-Dry' blotting system  Peqlab Biotechnologie GmbH, Erlangen, Germany 
real-time cell analyzer (RTCA) 
xCELLigence RTCA SP; Roche Diagnostics GmbH, 
Penzberg, Germany 
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Device Supplier 
Varioskan Flash Multimode Reader Thermo Scientific, Inc., Waltham, MA, USA 
Waterbath Memmert GmbH, Schwabach, Germany 
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4) Methods 
4.1) Bacterial cell culture 
4.1.1) Propagation and seeding 
 
   Bacterial E.coli XL1-blue strains, used for all conventional cloning 
procedures, were either cultured by agitation (225 rpm) in liquid LB-medium or 
on LB agar plates in an incubator at 37°C overnight. The selection for 
antibiotic–resistant progeny cells was achieved by addition of ampicillin [100 
μg/ml] due to the resistance cassette, which is included in all plasmid vectors 
used in this work.  
 
4.1.2) Transformation 
 
   In order to transform plasmid vectors into bacteria, 200 µl aliquots of 
competent E.coli XL1-blue were thawed on ice and approximately 100 ng of 
plasmid DNA was added. After 30 minutes of incubation on ice, the cells were 
heat-shocked at 42°C for 90 seconds and put back on ice for another 2 
minutes. Thereafter, 1 ml of antibiotic-free LB-medium was added and cells 
incubated at 37°C for another hour. Next, cells were centrifuged for 5 minutes 
at 2000 rpm and a large proportion of the supernatant was discarded in order 
to reduce the volume which was to be plated. Finally, the remaining cells were 
resuspended and plated on nutrient LB-agar containing ampicillin for 
cultivation over night. 
 
4.1.3) Purification of plasmid DNA from E.coli 
 
   For mini-prep of plasmid DNA, bacteria were inoculated in a volume of 5 ml 
of LB-medium, which was supplemented with ampicillin, and DNA was either 
isolated using the QIAprep Spin Miniprep Kit (Qiagen) according to the 
manufacturer`s protocol or via a self-made protocol:   
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   First, cells were pelleted for 5 minutes at 3600 rpm in a table-top centrifuge. 
The resulting pellet was resuspended in 250 µl buffer MP1, lysed by adding 
250 µl of buffer MP2 and incubated at room temperature for 5 minutes. The 
lysis buffer was then neutralized by adding 250 µl of buffer MP3 and the 
lysate was centrifuged for 10 minutes at 13000 rpm in a table-top centrifuge. 
Thereafter the supernatant was transferred into a new reaction tube, 700 µl of 
isopropanol was added and samples were vortexed. Precipitated DNA was 
centrifuged for 15 minutes at maximum speed, washed with 500 µl of 70% 
ethanol and centrifuged again for 5 minutes at maximum speed. After 
withdrawal of the ethanol the DNA was dried at room temperature and 
resuspended in 50 µl H2O. 
   For midi-prep the volume of LB-medium was 150 ml and the Pure Yield™ 
Plasmid Midiprep System (Promega) was used according to the 
manufacturer`s protocol.  
   The small-scale purification method was used preferentially, since it yields 
DNA of better quality leading to a higher transfection efficiency compared to 
the large-scale protocol.  
 
4.2) Mammalian cell culture 
4.2.1) Propagation of human cell lines 
 
   DLD1 and HCT116 colorectal cancer cells and their derivatives were 
maintained in McCoy’s 5A medium (Invitrogen) containing 10% fetal bovine 
serum (FBS). SW480, SW620, HCT15, CaCo2 and HT29 colorectal cancer 
cells, MiaPaCa2 human pancreatic cancer cells and human diploid fibroblasts 
(HDFs) were maintained in high glucose Dulbecco`s modified Eagles medium 
(DMEM, Invitrogen) containing 10% FBS. Colo320 colorectal cancer cells 
were propagated in RPMI 1640 medium supplemented with 10% FBS. All 
media were further supplemented with penicillin [100 U/ml] and streptomycin 
[100 μg/ml]. All cell lines were maintained at 37°C in a humidified atmosphere 
at 5% CO2. Cells were passaged every two to four days in order to avoid 
confluency.  
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4.2.2) Transfection of oligonucleotides, vectors and constructs 
 
   For the transfection of oligonucleotides, cells were trypsinized and seeded 
in the desired format, mostly into six-well plate wells. During trypsin treatment 
the transfection mix was set up. For transfection of oligonucleotides in a six-
well format the mix contained 100 µl Opti-MEM, 10 µl HiPerFect and 10 µl of 
oligonucleotide [10 µM] in order to achieve a final concentration of 100 nM. 
For the transfection of plasmids, the transfection mix consisted of 150 µl Opti-
MEM, 4 µg DNA and 5 µl FuGENE. For efficiency reasons the DNA was 
added to the Opti-MEM first, the transfection reagent was added last. 
   Before adding the mix drop-wise to the cells, it was incubated at room 
temperature for oligonucleotides 15, for plasmids 25 minutes. In case cells 
were selected in antibiotics, cells were incubated for 24 hours without the 
respective antibiotic first, to avoid additional stress, which could lead to cell 
death of successfully transfected cells.  
 
4.2.3) Cryo-preservation of mammalian cells 
 
   For cryo-preservation, sub-confluent, exponentially growing cells were 
trypsinized, pelleted by centrifugation at 300xg for 5 minutes and resuspended 
in 50% FBS, 40% growth medium and 10% DMSO (Roth). Aliquots in cryo-
vials were stored at -80°C for up to six months or, for long term storage, 
transferred into a liquid nitrogen tank.  
   For recovery, cells were rapidly thawed in a 37°C water bath and transferred 
into a 15 ml tube of pre-warmed growth medium. Cells were pelleted by 
centrifugation and resuspended in the respective growth medium for further 
cultivation. 
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4.3) Isolation of DNA 
 
   Genomic DNA from paraffin sections was isolated after overnight proteinase 
K digestion [0.1 mg/ml] in 0.1% SDS (Sigma) at 58°C with subsequent 
phenol/chloroform extraction (pH 8) and precipitation. Cellular DNA was 
isolated using the Blood & Tissue Kit (Qiagen) according to manufacturer’s 
instructions.  
 
4.4) Bisulfite treatment 
 
   For subsequent methylation analyses 200-1000 ng of DNA were treated 
with sodium bisulfite using the EZ DNA methylation kit (Zymo Research) 
according to the manufacturer’s instructions. This treatment converts 
unmodified cytosine residues to uracil, while methylated cytosine residues 
remain unaffected. These methylation-specific changes of the DNA sequence 
can be detected by different methods such as methylation specific PCR (see 
below) or bisulfite sequencing.  
 
4.5) PCR methods 
4.5.1) Colony PCR 
 
   For detection of insert positive transformants a bacterial culture tube 
containing selective medium was prepared in parallel with a 20 µl PCR master 
mix containing vector-specific primers (e.g. T7 fwd and SP6 rev for T-easy 
vectors), dNTPs, PCR buffer and FIREPol® DNA polymerase. A single colony 
was picked from the plate, transferred into the PCR tube and thereafter 
inoculated in the culture tube over night. If needed a replica-plate was used as 
well. 
   Representative PCR cycling conditions were the following: 95°C for 5 
minutes, followed by 25 cycles of 95°C for 20 seconds, 58°C for 30 seconds 
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and 72°C for 1 minute or longer, depending on the size of the insert. PCR 
results were controlled on a 1% agarose gel. 
 
4.5.2) Methylation specific PCR (MSP) 
 
   For the detection of DNA-methylation at the promoter sites of the miR-34 
genes, MSPs were performed using bisulfite treated DNA as a template (see 
above). MSP analyses were performed in a total volume of 20 µl using 1.5 
units Platinum Taq-polymerase (Invitrogen) per reaction and 30 ng of bisulfite 
converted DNA as template. The reaction conditions for miR-34a were the 
following: 95°C for 10 minutes, followed by 35 cycles of 95°C for 30 seconds, 
64°C for 30 seconds and 72°C for 30 seconds. The final elongation step was 
performed for 5 minutes at 72°C. Amplification conditions for miR-34b/c were: 
95°C for 10 minutes, followed by 40 cycles of 95°C for 30 seconds, 65°C for 
30 seconds and 72°C for 30 seconds. The final elongation step was 
performed for 5 minutes at 72°C.  
   Amplified fragments were separated by electrophoresis on 10% 
polyacrylamide gels and visualized by staining with ethidium bromide. 
Pictures were taken using a MultiImage Light Cabinet (Alpha Innotech). The 
oligonucleotide sequences used in this study are provided in the materials 
section. Addition of two inosines at the 5’-end of the miR-34a primer was used 
to increase the annealing temperature and hence achieve a decrease in 
unspecific PCR products. The MSP amplicon used for detection of miR-34a 
CpG-methylation is located within the only CpG island, which is present in the 
promoter and transcribed region of miR-34a. Therefore, it is likely that results 
obtained with this setup comprehensively represent relevant CpG-methylation 
affecting miR-34a expression.  
   In addition, it was previously shown in the Hermeking lab that the 
methylation detected by use of this PCR amplicon corresponds to results 
obtained with bisulfite sequencing of the promoter region and de-methylation 
of this region resulted in de-repression of miR-34a (Lodygin et al, 2008). 
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4.6) Isolation of RNA and reverse transcription 
 
   Total RNA was isolated using High Pure RNA Isolation Kit (Roche) 
according to the manufacturer’s protocol and eluted in 50 µl elution buffer. 
Amount and quality of the RNA were determined using a Nanodrop 
spectrophotometer. For analysis of mRNA levels cDNA was generated with 
the Verso cDNA Kit (Thermo Fisher Scientific) from 1 µg of total RNA using 
anchored oligo-dT primers. 
   For isolation of the RNA fraction enriched for small RNAs the High Pure 
miRNA Isolation Kit (Roche) was used according to the manufacturer’s 
instructions - either for cell lines or for FFPE tissue sections. cDNA was 
synthesized from 15 to 20 ng of RNA template using the TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems). 
 
4.7) qPCR/TaqMan 
 
   Real-Time PCR for analysis of mRNA levels was performed using a Light 
Cycler 480 System (Roche) and the Fast SYBR Green Master Mix (Applied 
Biosystems). Results were normalized to the mRNA levels of ‘house keeping 
genes’ like -actin or GAPDH. A list of qPCR-primers used for this study is 
provided in the materials section. 
   For detection of mature miR-34a expression, the TaqMan qPCR Detection 
Kit (Applied Biosystems) was used according to the manufacturer’s 
instructions. The measurement was performed in a Light Cycler 480 System 
(Roche) and results were normalized to RNU48 expression. 
 
4.8) Protein isolation and Western blot analysis 
 
   Cells were incubated and/or treated under the respective conditions, 
washed with ice-cold PBS and harvested on ice by using a plastic cell scraper 
and ice-cold RIPA buffer, which was supplemented with protease- and 
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phosphatase inhibitors (Roche) immediately before use. The cell 
suspension/lysate was further transferred into a new reaction tube and 
sonicated using a HTU SONI130 (G. Heinemann Ultraschall- und 
Labortechnik) for three consecutive five-second pulses with an intensity of 
85%. Thereafter remaining cells and debris were separated by centrifugation 
for 20 minutes at 14.000xg and 4°C and the supernatant, containing the 
protein lysate, was transferred subsequently into a new reaction tube. Unless 
used immediately, protein lysates were stored at -80°C. 
   Depending on the size of the analyzed proteins gels were prepared with 
polyacrylamide concentrations ranging from 7.5 to 12% and overlaid with a 
4% stacking gel.  
   Protein concentrations were determined using the BCA Protein Assay Kit 
(Pierce, Thermo Scientific) according to manufacturer’s protocol and 
concentration was determined in a Varioskan Flash Multimode Reader using 
the SkanIt RE for Varioskan 2.4.3 software (Thermo Scientific). 25-100 µg of 
protein were then diluted in an equal volume of 2xLaemmli buffer and 
denatured at 95°C for 5 minutes prior to loading on the gel together with a 
pre-stained protein ladder (Fermentas). Separation by electrophoresis was 
performed at 60-130 V in a Mini-PROTEAN®-electrophoresis system (Bio-
Rad) with Tris-glycine-SDS running buffer.  
   After separation the proteins were transferred from the Gel to an Immobilon-
P PVDF membrane (Millipore) in Towbin buffer using the PerfectBlue™ 
SEDEC 'Semi-Dry' blotting system (Peqlab) and a EPS 600 power supply 
(Pharmacia Biotech) at a constant amperage of 120 mA per gel and a 
maximum voltage of 10 V for 25-70 minutes, depending on the size of the 
analyzed protein. 
   To avoid non-specific binding during the subsequent antibody treatment the 
protein-containing membranes were incubated for one hour in 5% skim 
milk/TBS-T before. Thereafter primary antibodies were diluted in TBS-T and 
applied at 4°C over night or three hours at room temperature. Before and after 
incubation for one hour with the horseradish-peroxidase (HRP)-conjugated 
respective secondary antibody, membranes were washed in three 10-minute-
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steps in TBS-T. Detection of proteins was performed using a CF40 Imager 
(Kodak) and ECL/HRP substrate (Immobilon). 
 
4.9) Migration/Invasion assay in Boyden chambers 
 
   DLD1 and SW480 cells harboring doxycycline (DOX)-inducible pRTR 
vectors were cultured for 96 hours in presence or absence of DOX [100 
ng/ml]. Serum was deprived (0.1% FBS) for the last 24 hours before starting 
the assay. To avoid serum stimulation after trypsination, Trypsin was 
inactivated with Trypsin-neutralization solution (Clonetics) before seeding of 
the cells.  
   For a migration assay 5x104 cells were seeded in the upper compartment of 
a Boyden chamber (pore size 8.0 µm; Corning) containing serum-free 
medium and allowed to migrate towards the lower compartment, containing 
medium supplemented with 10% FCS as a chemo-attractant.  
   For invasion assays 7x104 cells were used and membranes were coated 
with Matrigel (BD Bioscience), which was solved in serum-free medium at a 
concentration of 3.3 ng/ml. After 48 hours the assay was stopped by fixing 
cells in ice-cold methanol for 10 minutes. After removing cells from the upper 
compartment, migrated cells were stained with DAPI [1 µg/ml] and pictures 
were taken using an Axiovert Observer Z.1 microscope connected to an 
AxioCam MRm camera in combination with the Axiovision software (Zeiss). 
For each condition three individual membranes were analyzed, five pictures 
were taken per membrane at random positions and cell number determined 
using fluorescence microscopy. The relative invasion/migration was 
expressed as the number of treated cells to control cells.  
 
4.10) Wound healing assay 
 
   Cells were seeded in medium with or without DOX [100 ng/ml] at high 
density one day before starting the experiment in order to obtain a confluent 
cell layer. Mitomycin C [10 µg/ml medium] was added to inhibit proliferation 
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two hours before scratching, using a 200 µl pipette tip or a culture insert 
(Ibidi). To remove floating cells, debris and Mitomycin C cells were washed 
twice with HBSS containing Ca2+ and Mg2+ (HBSS+/+). Thereafter, medium 
with or without DOX [100 ng/ml] was added and the cells were allowed to 
close the wound for 48 hours, while pictures were taken at regular intervals 
using an Axiovert Observer Z.1 microscope connected to an AxioCam MRm 
camera in combination with the Axiovision software (Zeiss). Per biological 
state three different measurements were performed per scratch in three 
independent wells.  
  
4.11) Sphere formation assay 
 
   For induction of sphere formation, adherent DLD1 cells were trypsinized and 
1x105 cells were seeded into a six-well coated with attachment preventing 
PolyHEMA (Sigma) using 5 ml sphere-medium (Yu et al, 2007). Right after 
seeding, the cells were transfected with either a control oligo or miR-34a [200 
nM] and treated with either water or SCF [10 ng/ml]. For all states 
experiments were carried out in triplicates. Resulting spheres were trypsinized 
again and quantified as well as employed for a second generation. For 
quantification, 1x104 cells/well were seeded in sphere-medium containing 1% 
methyl cellulose (Sigma) into PolyHEMA (Sigma) coated 96-well plates, at 
least six wells per unicate. The number of colonies larger than 50 µm in 
diameter was determined after seven days. Representative pictures were 
taken using an EOS 400D camera (Canon) at a 40-fold magnification. 
 
4.12) Soft agar colony formation assay  
 
   To measure anchorage-independent cell growth, the bottom of a 12-well 
was coated with 700 µl base agar containing 0.8% low melt agarose (Lonza), 
which was then covered with 700 µl 0.4% agarose containing 2x103 SW480 
cells, either transfected with miR-34a or control oligos 24 hours before, and 
incubated for 24 hours at 37°C and 5% CO2. 24 hours later 250 µl medium 
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was added, supplemented with either 10% FBS and either DOX [100 ng/ml] or 
water. Cells were incubated for 14 days changing the media every 3 days. For 
determination of colony numbers cells were stained with 50 µl of 0.005% 
crystal violet per well for two hours and de-stained in PBS over night at 4°C. 
Pictures were taken using an EOS 400D camera (Canon) and colonies were 
counted using image J software (http://rsbweb.nih.gov/ij/).  
 
4.13) Luciferase assay 
 
   To study binding of miRNAs to potentially matching sequences on the 
respective target mRNAs, a luciferase assay was performed. For this purpose 
the respective 3'-UTR was cloned down-stream of a luciferase gene. In case 
of successful binding, the luciferase gene transcription was targeted by the 
miRNA interaction and thereby upon addition of luciferase substrate the 
luciferase signal was lower than for a control oligonucleotide. 
   First, 3x104 H1299 or 1x106 SW480 cells were seeded into 12-well-plate 
wells. After 24 hours, cells were transfected with 100 ng empty pGL3 firefly 
luciferase reporter plasmid or molar equivalent of pGL3 containing the 
potential target sequence. Additionally, 20 ng of Renilla reporter plasmid were 
co-transfected as a normalization/transfection control together with the 
respective miRNA [25 nM], negative control oligonucleotide [25 nM] or 
antagomiR [50 nM].  
   After 48 hours of incubation the Dual Luciferase Reporter assay (Promega) 
was performed according to manufacturer’s instructions. Luminescence 
intensities were measured with an Orion II luminometer (Berthold) in 96-well 
format and analyzed with the SIMPLICITY software package (DLR). 
 
4.14) Site directed mutagenesis 
 
   To confirm the binding of miRNAs to the respective seed matching 
sequences, these had to be mutated in order to abolish the binding reaction. 
For this purpose site-directed mutagenesis was performed using the 
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QuickChange Mutagenesis Kit (Stratagene) according to manufacturer’s 
instructions. Cytosine and guanine residues were exchanged by mutagenesis 
preferentially, since the base pairing between these and their counter-bases is 
predicted to be stronger than binding between adenine and thymine. 
Oligonucleotides used for cloning and mutagenesis are provided on page 20. 
 
4.15) Flow cytometry 
4.15.1) Analysis of transfection efficacy 
 
   In order to control the transfection efficiency of the pRTR and pRTS vectors, 
both harbor either a green fluorescent protein (GFP) or red fluorescent protein 
(RFP) gene, respectively. The percentage of GFP/RFP-positive cells was 
determined after 72 hours without or following addition of DOX [100 ng/ml]. A 
BD AccuriTM C6 Flow Cytometer instrument (Accuri) and the corresponding 
CFlow® software was used to determine the proportion of fluorescent cells. 
  
4.15.2) Cell cycle analysis using propidium iodide 
 
   To analyze cell cycle distribution, cells were seeded and/or treated before 
transferring the supernatant, which includes dead and/or swimming cells, into 
a new falcon tube. The remaining, attached cells were washed with HBSS-/- 
and trypsinized at 37°C. Thereafter trypsin activity was abolished using the 
respective supernatant and the cell suspension was centrifuged for 4 minutes 
at 300xg. The cells were resuspended and fixed in one milliliter of ice-cold 
70% ethanol at -20°C overnight. After spinning down the pellet for 5 minutes 
at 4000 rpm in a table-top centrifuge, cellular DNA was then stained for one 
hour at 37°C using 400 µl propidium iodide (PI) staining solution, which had 
been passed through 0.22 μm sterile filter units (Millipore). DNA content was 
analyzed via PI fluorescence using a BD AccuriTM C6 Flow Cytometer 
Instrument (Accuri) and the corresponding CFlow® software. 1x104 cells were 
analyzed per sample.  
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4.16) Real-time cell analysis (xCELLigence) 
 
   A real-time cell analyzer (RTCA) was used to assess cell proliferation 
according to manufacturer’s instructions (xCELLigence Roche). 5x103 cells 
were seeded into each well of an E-plate 16. The seeded cells were allowed 
to equilibrate for at least 30 minutes in the tissue culture incubator, then 
transfected or treated with DOX [100 ng/ml] respectively before impedance 
was recorded every 60 minutes. After 24 hours 5-FU was administered. Cell 
growth monitoring was continued every 60 minutes for up to 48 hours. The 
electrical impedance was represented as a dimension/unit-less parameter 
termed cell-index which represents relative change in electrical impedance 
that occurs in the presence and absence of cells in the wells. This change is 
calculated based on the following formula: CI = (Zi −Z0)/15, where Zi 
determines the impedance at an individual experimental time point and Z0 is 
the impedance measured at the beginning of the experiment. The impedance 
is measured at three different frequencies (10, 25 or 50 kHz) and a specific 
time (Reference: Roche Diagnostics GmbH. Introduction of the RTCA DP 
Instrument. RTCA DP Instrument Operator‘s Manual, A. Acea Biosciences, 
Inc.; 2008.).  
 
4.17) Immunofluorescence 
 
   In order to analyze the localization/expression of cellular proteins, cells were 
seeded on glass cover-slides and cultivated under the desired conditions. For 
fixation cells were first washed three times with PBS, then treated with 4% 
paraformaldehyde, which was solved in PBS, for 10 minutes, washed with 
PBS and permeabilized in 0.2% Triton X in PBS for 15 minutes.  
   After blocking 30 minutes with 100% filtered FBS, cell slides were incubated 
with the pre-blocked first antibody in a solution of 0.05% Tween20 (Sigma) 
and 50% FBS in PBS for one hour in a humidity/dark chamber. The respective 
antibodies are listed in the materials section. Thereafter, slides were washed 
three times in PBS-T (0.05%) and pre-blocked secondary antibody was 
applied in a solution of 0.05% Tween20 and 50% FBS in PBS for 30 minutes 
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in the humidity/dark chamber. Finally, cells were washed again three times in 
PBS-T (0.05%) and nucleic chromatin was counter-stained by adding DAPI 
(Roth) in the last washing step, before covering the slides using ProLong Gold 
antifade (Invitrogen). As a control each staining was carried out without 
primary antibody.  
   For the detection of stress-fiber forming F-actin, Alexa Fluor 647-labeled 
Phalloidin (Invitrogen) was used. This is a heptapeptide which specifically 
binds at the interface of adjacent F-actin subunits.  
   Pictures were taken using laser scanning microscopy (LSM). For this 
purpose a confocal LSM 700 (Zeiss) was used with a Plan Apochromat 
20x/0.8 M27 objective, the ZEN 2009 software (Zeiss) and the following 
settings: image size 2,048 x 2,048 and 16 bit; pixel/dwell of 25.2 μs; pixel size 
0.31 μm; laser power 2%; master gain 600-1000. 
 
4.18) Scoring of immunohistochemistry signals 
 
   For quantification of the c-Met expression the previously published H-score 
was applied (Camp et al, 1999; Uddin et al, 2010). Each region of the tumor 
was assigned an intensity score from 0 to 3: 0 indicates no staining, 1 an 
incomplete and 2 and 3 complete staining with ascending intensity. The 
proportion of the tumor staining for the respective intensity was recorded as 
5% increments from a range of 0–100. A final H-score with a possible range 
from 0 to 300 was obtained by adding the sum of scores obtained for each 
intensity and proportion of area stained. Cases showing an H-score above the 
median (median=176.5) were categorized as high grade expression, whereas 
cases with a lower score were classified as low grade expression.  
   Nuclear Snail expression was evaluated using the following score: 0 no, 1 
weak, 2 moderate and 3 strong staining. Subsequently, the samples were 
assigned to two groups with either low (scores 0 and 1) or high Snail 
expression (scores 2 and 3). Since transcriptionally active Snail is only 
localized in the nucleus, the detection of cytoplasmic Snail expression was not 
considered in this analysis.  
Methods 
 
40 
 
   The staining score for nuclear expression of -catenin was assigned as 
published previously (Neumann et al, 2012a). 
   For detection of p53, nuclear staining was evaluated for both, frequency and 
intensity of stained nuclei. Intensity values were categorized as follows: 0-no 
staining, 1-weak, 2-moderate, and 3-strong staining. When more than 70% of 
tumor cell nuclei were stained and the intensity was at least moderate (score 
2) or strong (score 3), p53 expression was considered to be “high”. 
Cytoplasmic p53 staining was not included in further statistical analysis.  
   All immunohistochemical detections were evaluated independently by two 
observers (Dr. med. Jens Neumann and Helge Siemens for c-Met, Dr. med. 
Jens Neumann and Rene Jackstadt for Snail and Prof. Dr. med. Thomas 
Kirchner and Dr. med. Jens Neumann for p53). Discrepant evaluations were 
discussed and a consensus was reached. 
 
4.19) Statistical analysis 
 
   During this study different tests were applied in order to qualitatively 
evaluate statistical significant differences for different types of data 
constellation: For analysis of patient data calculations were conducted using 
SPSS software 19 (SPSS Inc.). For instance, a paired t-test was applied when 
comparing continuous outcomes (e.g. IHC scores) from two groups, e.g. case 
and control. Classification of cases into ‘high’ and ‘low’ populations, e.g. miR-
34a expression, was conducted using the median of the total population as a 
cut-off. For illustration purposes box plots were generated using the SPSS 
chart builder tool and data were reported as median, first and third quartile 
while whiskers indicate maximum and minimum and single dots indicate 
outliers. For the comparison of two continuous variables the Pearson 
correlation algorithm was applied for the generation of Pearson correlation 
coefficient (r) and statistical significance (p-value). A p-value of ≤ 0.05 was 
considered as statistically significant. Correlations were illustrated by the 
generation of a scatter/dot plot using the SPSS chart builder tool. In some 
cases a partial regression line was added in order to emphasize the 
respective correlation. 
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   Conditional logistic regression was used to quantitatively determine the 
simultaneous prognostic potential of several factors with respect to distant 
metastases. Age and gender were added as nuisance parameters to adjust 
for corresponding influences (Breslow & Day, 1987). The algorithms for Cox 
regression were used to calculate the conditional logistic regression as 
described previously (Krailo & Pike, 1984). The significant regression 
coefficients determined by multivariate analysis were further used to derive a 
prognostic score. A log-linear model was used to assess the relevance of the 
score with respect to case–control matching. These analyses were performed 
with the help of Prof. Dr. rer. nat. Ulrich Mansmann. 
   For evaluation of the remaining data like in vitro assays, qPCR results and 
other non-patient-related results a t-test was performed using the TTEST 
function in EXCEL (Microsoft Office). In all analyses a p-value of ≤ 0.05 was 
considered significant. 
 
4.20) Sequencing 
 
   In order to verify DNA sequences, e.g. of miR- or protein-coding vectors, a 
Sanger sequencing reaction was performed using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Life Technologies) according to the 
manufacturer’s protocol. One µg of DNA was supplemented with 5 pmol of 
primer and kit components were added to a total reaction volume of 10 µl. 
Amplification was carried out in 15 cycles, with ten seconds at 96°C, followed 
by 90 seconds at 60°C each. Thereafter, samples were cooled down to 25°C. 
To remove dye terminators from sequencing reactions, the DyeEx 2.0 Spin Kit 
(Qiagen) was used according to the manufacturer’s protocol in a 5417C 
centrifuge (Eppendorf). Purified DNA was then diluted in Hi-Di formamide 
(Applied Biosystems), incubated at 90°C for 3 minutes and loaded onto an 
ABI3130 genetic analyzer capillary sequencer (Applied Biosystems). Data 
evaluation was then performed using the 3130 Data Collection Software v3.0 
and the sequencing analysis software 5.2 (Applied Biosystems).  
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5) Results 
5.1) miR-34 and Snail form a double-negative feedback loop 
controlling EMT 
 
The results presented in this section are part of the publication: Siemens H*, 
Jackstadt R*, Hünten S*, Kaller M*, Menssen A*, Götz U and Hermeking H 
(2011). miR-34 and SNAIL form a double-negative feedback loop to regulate 
epithelial-mesenchymal transitions. Cell Cycle 10 (24), 4256-71. (* These 
authors contributed equally to this work). Contributions of the co-workers are 
indicated in the text and in the figures legends. 
 
5.1.1) Snail is directly targeted by miR-34 during p53-mediated MET 
 
   Recent reports described that p53 inhibits EMT (Chang et al, 2011; Kim et 
al, 2011d). Since miR-34a and miR-34b/c are well known p53 target genes, 
we hypothesized that they could likewise be involved in this process. In order 
to investigate these putative regulations, my colleague Sabine Hünten, 
another Dr. rer. nat. student in our group, analyzed the colorectal cancer cell 
line HCT116 and an isogenic clone, which carried a homozygous deletion of 
p53 (Bunz et al, 1998). In order to activate p53, the cells were treated using 
Nutlin-3a, which inhibits MDM2 (mouse double minute 2 homolog). The 
MDM2 ubiquitin-protein ligase inhibits p53 function by mediating its 
degradation (Vassilev et al, 2004). When the levels of the zinc-finger EMT-TF 
Snail were analyzed in the aforementioned cells, Western blot analyses 
revealed that it was expressed at higher levels in the p53-deficient 
background (Figure 3). Upon induction of p53 with Nutlin-3a, Snail levels 
decreased, while the epithelial marker protein and Snail target E-cadherin 
showed increased levels.  
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Figure 3: p53-dependent regulation of Snail protein in HCT116 
colorectal cancer cells. HCT116 p53+/+  and HCT116 p53-/- cells were  
treated with Nutlin-3a for the indicated periods. The indicated proteins 
were detected by Western blot analysis. β-actin served as a loading 
control. Sabine Hünten performed the analysis and generated the figure. 
 
   These results confirmed that expression of p53 negatively influences the 
expression of Snail protein. In a subsequent experiment, Sabine Hünten 
isolated RNA from cells treated as in Figure 3. By qPCR analysis she found 
that the miR-34 family was induced on level of the primary transcript upon 
induction of p53 (Figure 4). In accordance with the results obtained before, 
the mRNA levels of E-cadherin were up-, the levels of Snail and Vimentin 
down-regulated. In the p53-deficient HCT116 cells, these genes did not show 
significant expression changes after Nutlin-3a treatment. 
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Figure 4: p53-dependent regulation of Snail mRNA, miRNAs and EMT-
related factors in HCT116 colorectal cancer cells. p53+/+  and p53-/-  
HCT116 cells were treated with Nutlin-3a for the indicated periods. 
Expression of the indicated mRNAs was determined by quantitative real -
time PCR (qPCR) analyses. Fold changes represent mean values of 
triplicate analyses of Nutlin-3a vs. DMSO treated cells normalized to β-
actin expression. Data are represented as mean ± SD (n=3). Sabine 
Hünten performed the analyses and generated the figure. 
 
   Similar results were obtained by Sabine Hünten using cells pools of the 
colorectal cancer cell line SW480 transfected with the DOX-inducible p53 
expression vector pRTR (Figure 5): induction of ectopic p53 led to a 
pronounced reduction of Snail protein levels. This effect could be abolished by 
transfection of the cells using a miR-34a-specific antagomiR, showing that the 
p53-mediated Snail down-regulation was dependent on and mediated, at least 
in part, by miR-34a. 
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Figure 5: Regulation of Snail by p53 in SW480 colorectal cancer cells 
depends on miR-34a. Protein lysates of SW480 cells harboring a pRTR-
p53-VSV vector were subjected to Western blot analysis. Cells were 
transfected with the indicated oligonucleotides for 48 hours in the 
presence or absence of DOX for the last 24 hours prior to lysis. 
antagomiR-34a and antagomiR-control represent oligonucleotides 
specifically targeting miR-34a and the respective control. β-actin served 
as a loading control. Sabine Hünten performed the analyses and 
generated the figure. 
 
   To study, whether this regulation was direct or indirect, my colleague Dr. rer. 
nat. Markus Kaller analyzed the Snail 3'-UTR for potential miR-34 binding 
sites using the targetSCAN and Miranda algorithms (Grimson et al, 2007; 
John et al, 2004). This revealed a conserved miR-34 seed-matching site, 
which was further confirmed by Dr. rer. nat. Markus Kaller in a dual-reporter 
luciferase reporter assay with a Snail 3'-UTR harboring either a wild-type or a 
mutated miR-34 site (Figure 6). While luciferase activity of the construct 
harboring the wild-type Snail 3'-UTR was diminished upon transfection of the 
miR-34 family members, the construct carrying the mutated miR-34 site in the 
Snail 3'-UTR was not responsive to ectopic miR-34.  
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Figure 6: miR-34a/b/c regulates Snail via a conserved seed-matching 
site. a) Schematic depiction of the miR-34 seeds and seed-matching 
sequences in the 3'-UTR of the Snail mRNA and phylogenetic 
conservation among species. The position of the miR-34 seed-matching 
sequence in the Snail 3'-UTR is depicted as a black vertical bar. b) Dual 
reporter assay in H1299 cells transfected with miR-34a/b/c mimics (pre-
miR-34a/b/c) or control oligos and the indicated reporter constructs for 
the human Snail 3'-UTR. The targeted mutation of the Snail 3'-UTR is 
shown below. Data are presented as mean ± SD (n=3). Student’s t-test 
was used for comparisons, with p ≤ 0.05 considered significant. Dr. rer. 
nat. Markus Kaller performed the analyses and generated the figure.  
  
   These results confirmed that miR-34 directly binds to the Snail mRNA and 
thereby negatively regulates its expression. Subsequently, I addressed the 
question, whether this regulation leads to an epithelial phenotype and MET of 
mesenchymal CRC cell lines. 
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5.1.2) miR-34a inhibits EMT 
 
   In order to determine, whether miR-34a expression alone is sufficient to 
mediate MET in the CRC cell line SW480, which has a mesenchymal 
phenotype, miR-34a was ectopically expressed in SW480 cell pools 
transfected with the DOX-inducible pRTR vector. Similar to ectopic p53 
expression, expression of miR-34a resulted in a down-regulation of Snail 
protein (Figure 7a) and mRNA (Figure 7b). Accordingly, the Snail target E-
cadherin showed higher expression levels in cells with miR-34a induction 
compared to untreated cells. This was accompanied by decreased expression 
of the mesenchymal marker Vimentin on mRNA and protein level.  
 
 
 
Figure 7: Ectopic expression of miR-34a in SW480 cells causes 
down-regulation of Snail and mesenchymal markers. a) SW480 cell 
pools carrying the pRTR-miR-34a vector were treated with DOX for the 
indicated periods. The indicated proteins were detected by Western blot 
analysis. -tubulin served as a loading control. b) qPCR analysis of 
mRNAs corresponding to cells and proteins described in a). Bar charts 
and error bars represent mean and standard deviation of three 
independent experiments for each time point. Expression changes were 
normalized to -actin mRNA. 
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   Moreover, ZEB1, -catenin and HDAC1 were repressed on the protein level 
(Figure 8a) and less nuclear -catenin was detected by immunofluorescence 
(Figure 8b) upon induction of miR-34a compared to untreated SW480 cells. 
Besides the direct down-regulation of Snail by miR-34a, these effects may 
also contribute to miR-34a-mediated MET, since the TCF4/-catenin signaling 
pathway is able to induce Snail expression and HDAC1 has previously been 
shown to serve as a co-repressor for Snail (reviewed by Peinado et al, 2007).  
 
 
 
Figure 8: Ectopic expression of miR-34a causes down-regulation of 
ZEB1,  -catenin and HDAC1 in SW480 cells. a) Detection of the 
indicated proteins using Western blot  analysis of SW480 cells carrying 
the pRTR-miR-34a vector and treated with DOX for the indicated periods. 
-tubulin served as a loading control. b) Immunofluorescence analysis of 
-catenin in SW480/pRTR-miR-34a cells either untreated (upper panel) or 
treated with DOX for 48 hours (lower panel). Nuclei were counter-stained 
with DAPI. Pictures were taken at a 200-fold magnification. Scale bars 
represent 50 μm. 
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   Since EMT has been linked to the induction of tumor cell stemness (Thiery 
et al, 2009), different markers and mediators of stemness were analyzed on 
mRNA level under the conditions described above (Figure 9). Upon ectopic 
expression of miR-34a, the expression of CD133, OLFM4, BMI-1, CD44 and 
c-Myc mRNAs was repressed. The latter two represent previously published 
miR-34a targets (Christoffersen et al, 2010; Liu et al, 2011).  
 
 
 
Figure 9: Regulation of stemness-related mRNAs upon miR-34a 
induction in SW480 cells. SW480 cells carrying the pRTR-miR-34a 
vector were treated with DOX for the indicated periods.  Bar charts and 
error bars represent the mean and standard deviations of three 
independent experiments for each time point. Results were normalized to 
-actin mRNA expression. 
 
   Taken together, these changes indicated an inhibition of mesenchymal 
properties and potential loss of stemness upon ectopic expression of miR-
34a. Next, the question was addressed, whether the molecular changes, 
observed after induction of miR-34a in SW480 cells, had an impact on EMT-
associated cellular functions. For this purpose SW480/pRTR-miR-34a cells 
were subjected to three different assays: wound closure, migration and 
invasion were determined in the presence or absence of DOX. Wound closure 
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was significantly diminished by addition of DOX, as well as migration and 
invasion, which were reduced about 80% (Figure 10). Therefore, miR-34a is 
sufficient to induce MET and diminish wound closure, cellular migration and 
invasion. 
 
 
Figure 10: Decreased migratory capacities upon induction of miR-34a 
in SW480 cells. SW480 cells carrying the pRTR-miR-34a vector were 
subjected to wound closure-, migration- and invasion assays without or 
following stimulation with DOX. Bar charts and error bars represent mean 
and standard deviation of three independent experiments  for each assay 
and condition. Statistical relevance was calculated using the Student’s t -
test considering p ≤ 0.05 significant and indicated by  *.  
 
   These results raised the question, whether the observed inhibitory effects 
on cellular migration were dependent on the miR-34a-mediated reduction of 
Snail expression. To address this issue, a Snail cDNA sequence, which was 
tagged with VSV and lacking the 3'-UTR, and therefore was miR-34a 
resistant, was cloned into the DOX-inducible expression vector pRTR and 
transfected into SW480 cells.  
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   Next, cells were transfected with miR-34a oligonucleotides in the presence 
or absence of DOX and protein expression was analyzed (Figure 11). Similar 
to vector-driven miR-34 expression (Figure 7) transfection with the miR-34a 
oligonucleotides resulted in a decrease of Snail protein, while transfection with 
a control oligonucleotide did not. In contrast, addition of DOX significantly 
increased the Snail protein level even in the presence of the miR-34a oligos.    
 
 
 
Figure 11: Ectopic Snail expression is not affected by miR-34a 
mimics in SW480 cells. Western blot analysis of Snail protein in SW480 
cells carrying the pRTR-Snail construct either transfected with control - or 
miR-34a oligo for 48 hours and treated with or without DOX for the last 24 
hours. -tubulin served as a loading control.  
 
   Next, these cells were subjected to wound closure and migration analyses 
(Figure 12). The inhibitory effect of miR-34a oligonucleotide transfection on 
wound closure was less pronounced when compared with ectopic expression 
from the pRTR vector (Figure 10) but still significant. As shown in Figure 12, 
the effect on migration was almost identical to the results obtained with pRTR-
miR-34a. However, when adding DOX to the cells, and thereby ectopically 
expressing miR-34-resistant Snail protein, these effects could be reverted and 
migration was significantly restored.  
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Figure 12: Restoration of migratory properties in miR-34a treated 
SW480 cells by ectopic Snail expression. SW480 cells carrying the 
pRTR-Snail vector were transfected with either scrambled (control) or 
miR-34a oligo and treated with or without DOX (as described for Figure 
11) and subjected to wound closure- and migration assays. Bar charts 
and error bars represent mean and standard deviation of three 
independent experiments for each assay and state. Statistical relevance 
was calculated using the Student’s t -test with p ≤ 0.05 considered to be 
significant and indicated by  *.  
 
   Consequently, the down-regulation of Snail seems to be a key mediator of 
miR-34a-mediated suppression of migration in SW480 colorectal cancer cells.    
 
5.1.3) Snail binds to the miR-34a promoter and represses its expression 
 
   Previous studies had reported a negative feedback-loop between ZEB1/2 
and the p53-induced miR-200 family (Bracken et al, 2008; Burk et al, 2008). 
While the miRNAs down-regulate the EMT-TFs via binding to seed-matches 
in the 3'-UTR, their own transcription is targeted by ZEB proteins, which bind 
to E-boxes in the promoter regions of the miRNAs. This was reminiscent of 
what was found in this study: the miR-34 family is induced by p53 as well and 
Snail is also a Zinc-finger EMT-TF. Therefore, Dr. rer. nat. Antje Menssen 
hypothesized that miR-34 may also be suppressed by Snail and therefore 
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form a negative feed-back loop. To prove this hypothesis, the inducible 
expression vector pRTR-Snail was used to induce EMT in the colorectal 
cancer cell line DLD1, which has an epithelial phenotype. First, Snail 
expression and initiation of EMT was confirmed on molecular level by loss of 
E-cadherin shown by Western blot analysis (Figure 13).  
 
 
 
Figure 13: Characterization of a DLD1 cell pool conditionally 
expressing Snail. DLD1 cells carrying a pRTR-Snail-VSV construct were 
treated with DOX for the indicated periods. The indicated proteins were 
detected by Western blot analysis. Ectopic expression of Snail was 
controlled using an antibody directed against the VSV-tag. E-cadherin 
expression served as a marker for Snail-induced EMT in the cells. -
tubulin served as a loading control.  
 
   Furthermore, phase contrast microscopic evaluation revealed a transition 
from an epithelial and clustered morphology to a more mesenchymal, spindle- 
or fibroblast-like cell shape upon induction of Snail expression (Figure 14, left 
panel). This was accompanied by the disappearance of E-cadherin from the 
cellular junctions and stress-fiber formation, as shown by 
immunofluorescence for E-cadherin and F-actin (Figure 14, right panels).  
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Figure 14: Ectopic expression of Snail leads to EMT-like changes in 
DLD1 cells. DLD1 cells carrying the pRTR-Snail-VSV vector were either 
treated for 96 hours with DOX or left untreated. Morphological differences 
were determined using phase contrast microscopy (left panel). Confocal 
immunofluorescence analysis (other panels) was performed for the 
epithelial marker protein E-cadherin and the stress fiber-forming F-actin, 
which is associated with mesenchymal traits. Nuclei were counter -stained 
with DAPI. Pictures were taken at a 200-fold magnification and the scale 
bars represent 50 µm. 
 
   In accordance to the previous findings (Figure 12), ectopically induced Snail 
resulted in significantly increased migration, invasion and wound closure of 
the cells. This was measured by means of wound closure capabilities as well 
as in Boyden chamber assays for migration and invasion, all depicted in 
Figure 15. While the effect of ectopic Snail expression on the wound healing 
assay was less pronounced, it led to a severe increase of migration and 
invasion. 
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Figure 15: Analysis of EMT-associated processes after ectopic 
expression of Snail in DLD1 cells.  DLD1 cells carrying the pRTR-Snail-
VSV vector were subjected to the indicated assays in the presence 
absence of DOX. Bar charts and error bars represent mean and standard 
deviation of three independent experiments for each assay and state. The 
statistical significance of the results was determined using Student's t -
test, with data considered significant when p ≤ 0.05 and indicated by *.  
 
   In order to test whether Snail negatively regulates miR-34a expression, as 
Dr. rer. nat. Antje Menssen hypothesized, the levels of the primary miR-34a 
transcript were measured after adding DOX to DLD1 cells carrying the pRTR-
Snail vector. Interestingly, pri-miR-34a levels were reduced up to 95% after 96 
hours, which was accompanied by repression of the primary miR-200c 
transcript and E-cadherin mRNA as well as an increase in Vimentin and ZEB1 
(Figure 16). Since ZEB1 was previously shown to be a target of miR-200c the 
induction of ZEB1 by Snail may be due to the decreased expression of miR-
200c (Gregory et al, 2008). These regulatory loops may also explain the 
repression of ZEB1 protein by miR‑34a, depicted in Figure 8.  
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Figure 16: Ectopic Snail affects mRNA expression of EMT markers 
and primary miRNA transcripts. DLD1 cells carrying the pRTR-Snail-
VSV vector were treated with DOX for the indicated periods.  Bar charts 
and error bars represent the mean and standard deviations of three 
independent experiments for each time point. Changes in expression 
were normalized to -actin mRNA. 
 
   To confirm that the repression of miR-34a was specifically mediated by 
Snail and to exclude secondary effects, my colleague Rene Jackstadt, 
another Dr. rer. nat. student in our group, transfected SW480 cells with Snail-
specific siRNAs. This resulted in a marked decrease of Snail protein (Figure 
17a) and additionally in a pronounced de-repression of the primary transcripts 
of miR-34a and b/c (Figure 17b).  
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Figure 17: Inhibition of Snail restores expression of the primary miR-
34 transcripts. a) SW480 cells, naturally expressing relatively high levels 
of Snail, were transfected with a siRNA directed against Snail and 
decrease of the Snail protein was confirmed by Western blot analysis. -
tubulin served as loading control. b) Expression levels of the primary 
transcripts of miR-34a and miR-34b/c were measured by qPCR analysis 
with the indicated siRNAs for 48 h using -actin mRNA for normalization. 
Mean values ± SD (n=3) are represented as bar charts and error bars. 
Rene Jackstadt performed the analysis and generated the figure. 
 
   To analyze, if Snail represses the miR-34 genes, Rene Jackstadt screened 
the region around the two miR-34 TSSs for Snail binding sites (SBS). As 
depicted in Figure 18, two these were located in each of the miR-34 promoter 
regions and had high sequence homologies with the sites characterized for 
the E-cadherin promoter (Peinado et al, 2007). 
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Figure 18: Snail binding sites are located in the promoters  of miR-
34a/b/c and miR-200c. The location of predicted Snail binding sites 
(SBS) in the human miR-34a/b/c promoters is indicated by vertical arrows 
in the upper panel and dotted lines indicate previously characterized p53 
binding sites (p53BS). qChIP amplicons (see next f igure) are indicated by 
horizontal bars, transcriptional start sites (TSSs) by horizontal arrows. 
Detailed sequences are given below including phylogenetic sequence 
alignment of the SBS in the miR-34a, miR-34b/c, miR-200c/141 and 
CDH1/E-cadherin promoters. Rene Jackstadt performed the analysis and 
generated the figure. 
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   As proof for the direct binding of Snail to these sites, Rene Jackstadt 
demonstrated the Snail occupancy of the promoters by chromatin immuno-
precipitation (ChIP). The binding to the E-cadherin promoter served as a 
positive control and was even more pronounced than for miR-34a, which was 
more prominent than Snail binding to both sites in the promoter of miR-34b/c 
(Figure 19). 
 
 
Figure 19: Direct regulation of miR-34a/b/c and miR-200c by Snail. 
qChIP analysis of DLD1 cells 24 hours after activation of Snail-VSV 
expression by addition of DOX [100 ng/ml] using anti-VSV and anti rabbit 
IgG for ChIP. Binding to the E-cadherin promoter was used as a positive 
control. Binding to the Acetylcholine receptor promoter (AchR) served as 
a negative control. Experiments were performed comparing DOX-induced 
with untreated cells. Results represent the mean ± SD (n=3). Rene 
Jackstadt performed the analyses and generated the figure. 
 
   Taken together these data establish a negative feedback loop consisting of 
the EMT-TF Snail and miR-34. These regulations could be of importance in 
cancer, since their deregulation may shift cells to the mesenchymal state and 
thereby promote metastasis.  
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5.2) Epigenetic silencing of miR-34a and expression of its targets 
can predict distant metastases in colon cancer 
 
The results presented in this section have been published: Siemens H*, 
Neumann J*, Jackstadt R, Mansmann U, Horst D, Kirchner T and Hermeking 
H (2013). Detection of miR-34a promoter methylation in combination with 
elevated expression of c-Met and β-catenin predicts distant metastasis of 
colon cancer. Clinical Cancer Research 19 (3), 710-20. (* These authors 
contributed equally to this work). Contributions of the respective co-workers 
are indicated in the text and the figure legends. 
 
5.2.1) miR-34a is down-regulated via CpG-methylation in colon cancer 
with distant metastases 
 
   As previously mentioned, EMT is known to play an important role for the 
development of metastasis and according to the present literature, low levels 
of miR-34a are associated with elevated risk for metastases in breast cancer, 
as well as advanced stages and relapse in several types of solid tumors 
(Brabletz, 2012b; Corney et al, 2010; Gallardo et al, 2009; Peurala et al, 2011; 
Tanaka et al, 2011). Since previous studies identified promoter hyper-
methylation as frequent mode of miR-34 silencing in colorectal cancer 
samples and miR-34b/c methylation was associated with metastases in 
several cancer types including colon cancer, the question was addressed, 
whether there was a connection between these results and the regulatory 
events observed in this study so far (Lujambio et al, 2008; Vogt et al, 2011). 
As a hypothesis, silencing of miR-34a in the primary tumor was assumed to 
lead to an up-regulation of its target genes, among them the EMT-TF Snail. 
As a result, the primary tumor cells would undergo EMT and gain 
mesenchymal properties like increased migration and invasion abilities, 
stemness or resistance to apoptosis, which would then lead to formation of 
metastases at distant sites throughout the body.   
   To address this question, a patient sample collection, consisting of 94 
adenocarcinoma samples from resected colorectal tumors, was generated by 
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Dr. med. Jens Neumann. The collection was grouped into 47 pairs, matched 
for tumor grade, localization and extent (T classification). Each pair was 
composed of a case and a control sample. The case samples represented a 
primary tumor sample from a patient with distant metastases to the liver within 
five years after resection of the primary tumor (M1). The control counterpart 
represented a primary tumor sample from a patient with disease-free survival 
for at least five years after surgery (M0).  
   First, tumor DNA was isolated, treated with bisulfite and subjected to a 
methylation-specific PCR (MSP), in order to determine the methylation pattern 
of the miR-34a and b/c promoters (Figure 20). 93 and 86 samples showed a 
MSP product for the miR-34a and b/c promoter amplicon, respectively. 
Possible explanations for non-detectable PCR products in one and eight 
cases may be insufficient amounts of template and/or loss of the 
chromosomal loci as published before (Fijneman et al, 2007; Lee et al, 2000). 
The positive MSP results were as follows: methylation of the miR-34a 
promoter was detected in approximately 45% (42 of 93), methylation of miR-
34b/c in approximately 92% (79 of 86) of the cases, respectively.  
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Figure 20: MSP analysis of miR-34a and b/c promoters in colorectal 
cancer samples with and without distant metastases. DNA was 
isolated from colon cancer samples either with (M1) or without (M0) 
distant metastases, treated with bisulfite and used as template for 
methylation specific PCR. Representative results are shown for miR-34a 
(upper panel) and miR-34b/c (lower panel). M and U represent methylated 
or unmethylated alleles, respectively.  Water was used instead of a 
template in a negative control reaction, and genomic DNA from human 
diploid fibroblasts (HDF) served as biological negative control. MiaPaCa2 
and CaCo2 DNA served as positive controls for miR-34a and miR-34b/c 
methylation, respectively (Lodygin et al, 2008; Toyota et al, 2008).   
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   Notably, the proportion of hyper-methylated miR-34a promoters was 
significantly elevated in M1 samples (30 of 46) compared to M0 samples (12 
of 47), summarized in Table 1. Additionally, miR-34a methylation significantly 
correlated with the status of lymph node metastases. About 54% of cases with 
lymph node metastases (N+) showed a methylation of the miR-34a promoter, 
while this was only the case in about 31% of the lymph node metastases-free 
(N0) samples. Other parameters like gender, tumor size or -grade were not 
significantly associated with miR-34a or miR-34b/c methylation according to a 
first analysis using the Pearson correlation algorithm.  
 
 
Table 1: Association of miR-34a promoter methylation events with 
clinico-pathological parameters. Results obtained by MSP were 
correlated with several clinical parameters. miR-34a promoter methylation 
significantly correlated with distant and lymph node metastases. N+ 
indicates the presence of one or more lymph node metastases. p-values 
of ≤ 0.05 were regarded as statistically significant.  
 
   Methylation of miR-34b/c did not associate with any of the parameters 
analyzed in this study. As mentioned above the overall methylation frequency 
was relatively high (approximately 92%). This corresponds to previous 
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studies, which showed that miR-34b/c methylation is a very frequent event in 
colorectal cancer in general (Kalimutho et al, 2011; Toyota et al, 2008; Vogt et 
al, 2011). Therefore, the use of miR-34b/c methylation as a biomarker was not 
further analyzed in this study. 
   Next, I addressed, whether the miR-34a promoter CpG-methylation results 
in lower expression levels of the mature miRNAs. Since miR-34b/c promoter 
methylation was almost ubiquitously present in our collection and miR-34c 
expression was shown to be about 300-fold lower than miR-34a in a small 
subset of tumor samples (n=6; data not shown) and in previous studies, the 
further analyses were focused on the silencing of miR-34a (Kalimutho et al, 
2011; Toyota et al, 2008; Vogt et al, 2011). Expression of the mature miRNA 
was measured by a probe-based TaqMan assay specific for miR-34a. The 
expression of miR-34a showed a significant inverse correlation with the 
methylation of its promoter in the respective tumor samples (Figure 21). 
 
 
Figure 21: Correlative analysis of miR-34a expression and 
methylation of its promoter. Small RNAs were isolated from primary 
colon cancer samples either with (M1) or without (M0) distant metastases 
to the liver and employed as template in a miR-34a specific TaqMan 
assay. The left panel shows single bars representing miR-34a expression 
of each single case. The right panel shows box plots representing the 
entire populations of the methylated or unmethylated subgroups, 
respectively. Y-axis in the right panel is given in log 10 scale. The p-values 
were calculated with a paired t-test. 
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   In accordance to the correlation between miR-34a methylation and distant 
spread, elevated miR-34a expression showed a significant correlation with the 
absence of metastases to the liver (M0, Figure 22).  
 
 
Figure 22: Detection of mature miR-34a in colorectal cancer 
populations with and without distant metastases. Small RNAs were 
isolated from colon cancer samples either with (M1) or without (M0) 
distant metastases to the liver and used as a template in a miR-34a 
specific TaqMan assay. Left panel shows single bars representing miR-
34a expression of each single case. The right panel shows box plots 
representing the entire populations of the respective subgroups. Y-axes 
in both panels are given in log10 scale. The p-values were calculated with 
a paired t-test.  
 
   Analyzing the population on the basis of the matched pairs confirmed the 
previous results: miR-34a expression was increased in the M0 samples when 
compared to the respective M1-counterparts in ~68% (32 of 47) of the 
matched pairs (Figure 23). 
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Figure 23: Detection of mature miR-34a in single colorectal cancer 
cases with and without distant metastases. Small RNAs were isolated 
from colon cancer samples either with (M1) or without (M0) distant 
metastases to the liver and used as a template in a miR-34a specific 
TaqMan assay. The single bars represent miR-34a expression of each 
case as single bar arranged according to matched pairs. Black bars 
indicate the M1 samples; white bars represent the corresponding M0 
counterparts. Y-axis is given in a log10 scale.  
 
   Therefore, miR-34a expression is epigenetically silenced preferentially in 
primary colon cancers, which give rise to distant metastases. The subsequent 
analyses were aimed to determine, whether low miR-34a expression results in 
elevated expression of pro-metastatic miR-34-targets. 
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5.2.2) miR-34a expression inversely correlates with expression of its 
targets and clinico-pathological features 
 
   To clarify, whether the miR-34-mediated regulation of its downstream 
targets, like for instance Snail, was detectable in primary CRC as well and 
correlated with formation of metastases, immunohistochemical (IHC) analyses 
were performed on the tumor collection described in 5.2.1. The receptor 
tyrosine kinase c-Met as well as the transcription factors Snail and -catenin 
were examined, all of which are targeted by miR-34a and have previously 
been associated with distant spread in colorectal cancer (Brabletz et al, 2005; 
Fujita & Sugano, 1997; Hwang et al, 2011a; Kim et al, 2011b; Kim et al, 
2011c; Kudo-Saito et al, 2009; Li et al, 2009; Siemens et al, 2011). First, it 
was analyzed whether the expression of the proteins correlates with the miR-
34a expression data obtained before. While low miR-34a expression 
significantly correlated with elevated levels of c-Met and -catenin (p=0.031 
and 0.004; Figure 24, upper and lower panel), Snail expression did not 
correlate with miR-34a according to the Pearson algorithm (p=0.132; Figure 
24, middle panel). However, a weak correlation was determined using the 
Spearman algorithm (p=0.044, data not shown).  
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Figure 24: Correlation of the expression of miR-34a and its target 
proteins c-Met, Snail and  -catenin. Tissue sections of colorectal 
cancer samples were stained in order to determine protein expression of 
miR-34a targets and results were compared with miR-34a expression. In 
every panel the correlation between the respective target and miR-34a 
expression is plotted on the left. The consecutive pictures show 
representative immunohistochemical detections of either low or high 
expression of the respective protein. The upper panel shows results for c-
Met, the middle panel shows results for Snail and -catenin results are 
represented in the lower panel. The p-values were calculated applying the 
Pearson correlation algorithm. 
 
   Though inverse correlations between miR-34a and its targets were relatively 
weak, the expression of the respective proteins alone displayed significantly 
increased levels in the M1 samples in all three cases (p=0.001, 0.017 and 
0.005), as shown in Figure 25.  
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Figure 25: Correlation of miR-34a targets with distant metastases in 
colorectal cancer. Tissue sections of colorectal cancer samples were 
stained in order to determine protein expression of miR-34a targets and 
results were correlated with the presence of metastases. Y-axes 
represent expression levels of the respective miR-34a targets and boxes 
represent M0 and M1 subgroups. All p-values were calculated applying a 
paired t-test. 
 
   Additional analyses regarding the presence or absence of lymph node 
metastases were performed (Table 2), revealing strong correlations between 
the occurrence of metastases and the presence of miR-34 methylation and 
low miR-34 expression. However, miR-34a targets did not reach significant 
differences between the two groups.  
 
 
Table 2: Lymphatic spread correlates with the expression of markers 
analyzed in this study. N0 indicates the absence, N+ the presence of 
one or more lymph node metastases. Mean differences, 95% confidence 
interval (CI) and p-values were calculated using a paired t-test. 
Calculations were performed with the help of Prof. Dr. rer. nat. Ulrich 
Mansmann.  
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   Thereafter, the miR-34a expression data described before (see 5.2.1) were 
compared with clinical features previously evaluated in this tumor sample 
collection (Neumann et al, 2012a). This revealed significant correlations 
between miR-34a expression and loss of the protein encoded by the DNA 
repair gene hMLH1 as well as with microsatellite instability (MSI-H), shown in 
Figure 26. This is in line with the observation that the loss of hMLH1 
expression causes MSI-H in colon cancer (Bronner et al, 1994; Papadopoulos 
et al, 1994). 
 
 
Figure 26: Correlation of miR-34a expression with hMLH1 and 
microsatellite instability. Expression of mature miR-34a in colorectal 
cancer samples was assigned to a) expression of hMLH1 and b) 
microsatellite instability. Data are presented as box plots. Y-axes are 
given in log10 scale and p-values were calculated with a t-test.    
 
   Additionally, the miR-34a expression data were analyzed for correlations 
with activated BRAF, namely V600E mutation, and advanced age, which was 
previously found in model organisms (Christoffersen et al, 2010; Li et al, 2011; 
Liu et al, 2012). The V600E mutation affects the activating loop of the mature 
BRAF protein reaching from codon 596 to 600. It results in the permanent 
activation of BRAF and occurs in a subset of colorectal cancer (Cantwell-
Dorris et al, 2011). 
   According to the increased miR-34 expression in BRAF induced 
senescence (Christoffersen et al, 2010), miR-34a expression was significantly 
elevated in tumors with activating BRAF mutation (p=0.008, Figure 27a). 
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Moreover, elevated miR-34a expression in the tumor sample was associated 
with high age of the patients (p=0.013, Figure 27b). 
 
 
Figure 27: Correlation of increased expression of mature miR-34a 
with the activating BRAF mutation V600E and advanced age in 
colorectal carcinomas.  Panels show box plots representing miR-34a 
expression of the entire population stratif ied either for  a) BRAF mutation 
versus wild-type or b) age (using the median of the overall age as a cutoff 
for high and low age). Y-axes are given in log10 scale and p-values were 
calculated applying a t-test. 
 
    Interestingly, neither expression nor methylation of miR-34a was 
associated with the IHC expression pattern of p53 protein (data not shown).  
 
5.2.3) A new marker combination is highly predictive for the risk of 
distant metastases in colon cancer  
 
   Finally, the prognostic value for predicting the risk of distant metastases was 
evaluated for the markers, which were analyzed in this study. For this 
purpose, sample data were sub-divided into high- and low-expressing 
populations, using the total median as threshold, and subjected to conditional 
logistic regression (Table 3). As described for the Pearson algorithm, Snail did 
not significantly correlate with distant spread (M1), whereas miR-34a 
methylation, c-Met- and -catenin expression showed significant associations 
with metastases and exhibited comparatively high odds ratios (ORs). 
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Unexpectedly, miR-34a expression did not show a correlation with the 
absence of metastases, probably due to the simplifying assignment of the 
cases into high and low subpopulations. 
 
 
 
Table 3: Univariate correlation analysis of distant metastases with 
clinico-pathological variables analyzed for qualitative parameters in 
the matched case-control collection. After categorization, based on the 
respective overall median of expression, data were separated into 
populations with low (below the median) and high (above the median) 
populations. A multivariate conditional logistic regression  was applied to 
calculate the respective odds rat ios, p-values and the 95% confidence 
intervals (CI). Calculations were performed with the help of Prof. Dr. rer. 
nat. Ulrich Mansmann.  
 
   In order to exclude an influence of the confounding factors gender and 
patient’s age, a multivariate regression model was generated (Table 4). The 
results indicated a significant association of distant metastases with 
methylation of the miR-34a promoter and high expression of c-Met. However, 
-catenin expression was not significantly associated with M1 state but 
nevertheless exhibited a strong trend as indicated by a p-value of 0.058.    
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Table 4: Confounder-adjusted multivariate regression model for 
quantitative analysis of factors associated with metastasis formation 
in colon cancer. Unmatched confounding factors age and gender were 
added to the multivariate analysis to estimate their potential effects on 
the analyzed data. A multivariate conditional logistic regression was 
applied to calculate the respective ORs, p-values, and the 95% 
confidence intervals (CI). Calculations were performed with the help of 
Prof. Dr. rer. nat. Ulrich Mansmann.  
 
   Remarkably, miR-34a methylation, c-Met expression, and -catenin 
expression displayed similar ORs, indicating a similar prognostic power for 
distant metastases. Consequently, we evaluated the prognostic value of 
combinations of the markers analyzed here by generating an additive score, 
ranging from zero to three, which sums up the value of one or zero assigned 
for the presence or absence of miR-34a methylation, high c-Met and -catenin 
expression (Figure 28).  
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Figure 28: Combinatorial distribution of markers within the matched 
M0/M1 pairs. Numbers in the fields indicate number of pairs with the 
respective M0 and M1 score. Increased darkening indicates elevated 
abundance of the respective combination; white fields indicate the 
absence of adequate pairs. Calculations were performed with the help of 
Prof. Dr. rer. nat. Ulrich Mansmann. 
 
   In 31 of the 47 (approximately 66%) matched pairs, the M1 sample 
displayed a higher score value than the respective M0 counterpart, whereas 
in only six of the 47 studied pairs (12.8%), the M0 patient showed a higher 
marker score. For 10 pairs, no difference between case and control was 
determined. The difference of the combined score between case and control 
samples was statistically significant with a p-value of 0.029. Noteworthy, none 
of the M0 samples displayed a score larger than two and only three M1 
samples had a score of zero. Notably, 13 of the 94 (13.8%) primary tumor 
samples showed the maximum score of three, thereby representing the group 
of patients with the highest risk of distant metastases. 
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   To determine the practical relevance of combined marker detections, we 
conducted a hypothetical calculation of the risk for distant metastasis (Table 
5). Assuming a baseline risk of 0.2 (20%) if none of the markers is positive, 
the risk increases to about 0.48 (48%) if only one of the three markers is 
positive, to about 0.77 (77%) when two of the three markers are positive, and 
to about 0.92 (92%) if all three markers are detected.  
 
 
Table 5: Theoretical evaluation of the prognostic value of the marker 
combination for the prediction of metastases in colon cancer. Odds 
ratios (ORs) of single markers (see Table 4) and ORs for combinations of 
2 or 3 markers are listed. The risk column represents the result of a 
hypothetical calculation estimating the risk for distant metastases in 
dependence of expression of the markers analyzed in this study. For this, 
the baseline risk for metastases in the absence of detection of any of the 
3 markers was set to 20% (=0.2). The increasing darkness of grey 
shading indicates the increasing risk due to the number of detected 
markers (0–3). Calculations were performed with the help of Prof. Dr. rer. 
nat. Ulrich Mansmann. 
 
   Taken together, the combined detection of miR-34a CpG-methylation, 
elevated c-Met and -catenin expression emerged as the combination with 
the highest prognostic power for distant metastasis in this cohort of patients 
with colon cancer.  
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5.3) c-Kit is directly targeted by miR-34 upon p53 activation 
 
   The results presented in this chapter have been published: Siemens H, 
Jackstadt R, Kaller M and Hermeking H (2013). Repression of c-Kit by p53 is 
mediated by miR-34 and is associated with reduced chemoresistance, 
migration and stemness. Oncotarget 4 (9), August 6, advance online 
publications. The respective contributions of the co-workers are indicated in 
the text. 
 
5.3.1) c-Kit is repressed by ectopic expression of p53 and miR-34a in 
colorectal cancer cell lines 
 
   According to a recent study, the RTK c-Kit is repressed by p53 in murine 
hematopoietic stem cells (Abbas et al, 2011). However, the authors did not 
detect a direct binding of p53 to the c-Kit promoter. This led us to the 
hypothesis, that miR-34 may mediate the down-regulation of c-Kit expression 
after p53 activation. To analyze the potential regulation of c-Kit by p53, two 
different conditional systems were employed to express p53: SW480 cell 
pools transfected with the DOX-inducible vector pRTR expressing the p53 
ORF and a DLD1 single cell clone harboring a p53 allele under control of the 
tet-off system (Siemens et al, 2011; Yu et al, 1999). Although the endogenous 
levels of c-Kit were lower in SW480 cells than in DLD1 cells, in both cellular 
systems c-Kit protein expression was down-regulated following activation of 
p53 for 48 hours (Figure 29).  
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Figure 29: c-Kit protein levels are repressed after ectopic p53 in 
colorectal cancer cell lines. p53 was ectopically induced in the  CRC cell 
lines SW480 and DLD1 for 48 hours. The indicated proteins were 
detected by Western blot analysis. -tubulin served as a loading control. 
 
   Since miRNAs were shown to mediate gene repression by p53, we 
examined the c-Kit 3'-UTR using the Target-Scan algorithm (Lewis et al, 
2005). Thereby two potential miR-34 seed-matching sequences were 
identified in the 3'-UTR of c-Kit, which are depicted in Figure 30. While the 
first site, which is a perfect match to the miR-34a 8-mer seed-sequence, is 
relatively conserved among different species, the second site was less 
conserved. 
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Figure 30: Scheme of the c-Kit mRNA and conservation of the 
putative miR-34 seed-matching sequences among species. miR-34-
seed matches are represented as grey vertical bars in the c-Kit 3'-UTR 
(thin black line) . Detailed sequences of the two sites and phylogenetic 
homologies are shown below. Potential base pairing is shaded in grey.  
 
   To determine whether the differences in c-Kit protein were due to changes 
on mRNA level, and therefore potentially caused by miRNA activity, p53 was 
induced in SW480 and DLD1 cells for 72 hours, total RNA was isolated and 
employed as template for qRT-PCR (Figure 31). As expected, expression of 
the primary miR-34a transcript was induced. Furthermore, repression of the c-
Kit mRNA was observed after p53 activation in both SW480 and DLD1 cells. 
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Figure 31: qPCR analysis of pri-miR-34a and c-Kit mRNA levels in the 
colorectal cancer cell lines SW480 and DLD1 after p53 induction. p53 
was induced by addition or withdrawal of DOX for 72 hours. Results were 
normalized to -actin mRNA. Results represent the mean +/- SD (n=3) 
and significance was calculated applying a Student’s t -test. p-values ≤ 
0.05 are indicated by *.  
 
   Since the basal levels of miR-34b and c expression have been shown to be 
relatively low in colon cancer and therefore seem to be of minor functional 
relevance, we focused our further studies on miR-34a (Kalimutho et al, 2011; 
Toyota et al, 2008; Vogt et al, 2011). In order to test whether miR-34a 
expression alone is sufficient to down-regulate c-Kit, pri-miR-34a was 
expressed in SW480 and DLD1 cells using the conditional pRTR expression 
system. Indeed ectopic miR-34a reduced c-Kit mRNA levels in both cell lines 
(Figure 32). 
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Figure 32: qPCR analysis of c-Kit mRNA levels in the colorectal 
cancer cell lines SW480 and DLD1 upon ectopic miR-34a expression. 
miR-34a was induced by addition of DOX for the indicated periods. 
Results were normalized to -actin mRNA. Results represent the mean +/- 
SD (n=3) and significance was analyzed by a Student’s t-test. p-values ≤ 
0.05 are indicated by *.  
 
   To confirm that the regulation of c-Kit mRNA by miR-34a was accompanied 
by a decrease of the protein, corresponding protein lysates of DOX-treated 
SW480 and DLD1 cells were generated and subjected to Western blot 
analysis (Figure 33).  
 
 
 
Figure 33: Down-regulation of c-Kit protein expression upon 
induction of ectopic miR-34a in colorectal cancer cells. miR-34a was 
induced by addition of DOX for the indicated time points. The indicated 
proteins were detected by Western blot analysis. -tubulin served as a 
loading control.  
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   This revealed a concomitant decrease of the c-Kit protein after addition of 
DOX. Therefore, elevated miR-34a expression is sufficient to decrease c-Kit 
protein and mRNA levels. 
 
5.3.2) miR-34 directly targets c-Kit and mediates c-Kit down-regulation 
by p53 
 
   To determine whether the miR-34 family members bind to the predicted 
target sites in the c-Kit 3'-UTR, a dual luciferase reporter assay was 
performed. For this a 1245 bp fragment of the c-Kit 3'-UTR, including the two 
potential binding sites, was cloned downstream of a luciferase ORF. To 
additionally analyze whether one of the two sites is preferred by miR-34a, 
either both or one of the seed-matching sites were mutated (Figure 34). 
 
 
 
 
Figure 34: Schematic depiction of constructs used for dual luciferase 
assay. The luciferase gene is presented as grey box, the c-Kit 3'-UTR is 
presented as black horizontal bar and the positions of the miR-34 seed-
matching sequences in the c-Kit 3'-UTR are depicted as a grey vertical 
bars. The targeted mutation of the potential miR-34 sites are expressed 
as crossed out. Detailed base exchanges of the respective targeted 
mutations are given below.   
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   In the dual-reporter luciferase assay miR-34a as well as miR-34b and c 
significantly decreased the activity of the reporter representing the wild-type c-
Kit 3'-UTR compared to the empty control vector (Figure 35). When site 1 was 
mutated, we observed a strong de-repression, whereas mutation of site 2 
could not prevent the down-regulation of the luciferase activity. Mutation of 
both sites led to resistance against miR-34a regulation, but not to a de-
repression.  
 
 
Figure 35: miR-34 oligonucleotides repress a c-Kit reporter in a dual-
luciferase assay. Dual reporter assay in SW480 cells transfected with 
miR-34a/b/c mimics or control oligonucleotide and the indicated reporter 
constructs for the human c-Kit 3'-UTR. Data are represented as mean ± 
SD (n=3) and significance was calculated applying a Student’s t -test. p-
values ≤ 0.05 are indicated by *.  
 
   These results indicate that the miR-34 family targets the c-Kit mRNA using 
the first of the two tested binding sites and additionally substantiate the 
assumption that the first site is the preferred target sequence, since it is highly 
conserved among species.  
   In addition, p53-mediated down-regulation of c-Kit in DLD1 cells could be 
prevented by simultaneous transfection of an antagomiR directed against 
miR-34a (anti-miR-34a), while additionally transfected miR-34a further 
enhanced the repression of c-Kit when p53 was activated concomitantly 
(Figure 36).  
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Figure 36: Inhibition of miR-34a attenuates the p53-mediated 
degradation of c-Kit. DLD1/tTA-p53 cells were either transfected with a 
control oligonucleotide, miR-34a or an anti-miR directed against miR-34a 
for 24 hours and kept either in the presence or absence of DOX (without 
or with ectopic p53). The indicated proteins were detected by Western 
blot analysis. -tubulin served as a loading control.     
 
   Taken together, miR-34a therefore mediates the repressive effects of p53 
on c-Kit expression by directly targeting the c-Kit 3'-UTR via a single 
conserved seed-matching site.   
 
5.3.3) Ectopic expression of c-Kit overrides miR-34a-mediated inhibition 
of Erk signaling and colony formation in DLD1 cells 
 
   In order to determine the effects of the miR-34a-mediated decrease in c-Kit 
protein, we analyzed its impact on downstream signaling pathways. While 
phosphorylated Stat3 did not seem to be affected (data not shown), 
phosphorylated Erk levels were significantly decreased after miR-34a 
induction and the concomitant reduction of c-Kit in DLD1 cells, while un-
phosphorylated Erk levels remained unchanged (Figure 37). 
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Figure 37: Down-regulation of c-Kit by miR-34a negatively influences 
Erk signaling in DLD1 cells. DLD1 cells carrying the DOX-inducible 
vector pRTR-pri-miR-34a were treated with DOX for the indicated time-
points and cell lysates subjected to Western blot analysis using 
antibodies against the indicated proteins. -tubulin served as a loading 
control. 
 
   Next, it was determined whether the miR-34a-mediated decrease in Erk 
phosphorylation was dependent on the down-regulation of c-Kit. Therefore, 
DLD1 and SW480 cell pools were generated carrying a conditional expression 
vector for c-Kit lacking its original 3'-UTR. Without the miR-34 seed-matching 
sequence, ectopic c-Kit was expected to be resistant to degradation by miR-
34a. In line with the vector-driven miR-34a expression (Figure 37), 
transfection of these cells with a miR-34a oligonucleotide resulted in 
decreased levels of Erk phosphorylation in both cell lines, while the control 
oligo had no effect (Figure 38). Notably, induction of ectopic c-Kit largely 
reversed the effect of miR-34a on phosphorylated Erk, whereas the amount of 
total Erk was not affected. Collectively, these results show that the down-
regulation of c-Kit is necessary for the inhibitory effects of miR-34a on Erk 
signaling.  
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Figure 38: Ectopic (miR-34a-resistant) c-Kit prevents miR-34a-
mediated repression of Erk phosphorylation in CRC cell lines. SW480 
and DLD1 cells were transfected with oligonucleotides for 48 hours and 
DOX was added for 24 hours. Subsequently, Western blot analysis of the 
indicated proteins was performed. -tubulin served as a loading control. 
le: long exposure, se: short exposure. The cell pools of SW480/pRTR-c-
Kit were generated by Rene Jackstadt.  
 
   To test, whether these regulations would affect the capacity of SW480 cells 
to grow anchorage-independent in soft agar, which is known to be affected by 
Erk signaling (Wiesenauer et al, 2004), cells treated as in Figure 38 were 
seeded into soft agar and colony formation was measured (Figure 39). miR-
34a transfection severely reduced the number of colonies. The induction of 
ectopic c-Kit expression led to a slight but significant increase in the number 
of colonies, at least partially reflecting the results observed on the level of Erk 
phosphorylation.  
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Figure 39: The interplay of c-Kit and miR-34a influences colony 
formation of CRC cells. SW480 cells were treated as described in Figure 
38 and subjected to a colony formation assay. Results represent the 
mean +/- SD (n=3) and significance was calculated applying a Student’s t -
test. p-values ≤ 0.05 are indicated by *. The cell pools of SW480/pRTR-c-
Kit were generated by Rene Jackstadt. 
 
   In conclusion, Erk signaling downstream of c-Kit contributes to colony 
formation and can be suppressed by miR-34a. As demonstrated, this effect of 
miR-34a seems to depend, at least in part, on the down-regulation of the c-Kit 
receptor expression by miR-34a. 
   In a subsequent qPCR analysis, the EMT markers Vimentin and CDH1 as 
well as the primary transcript of miR-34a were not affected on mRNA level 
upon the ectopic expression of c-Kit in either SW480 (Figure 40a) or DLD1 
cell pools (Figure 40b).  
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Figure 40: EMT markers and the primary miR-34a transcript are not 
regulated upon induction of c-Kit. SW480 a) and DLD1 cells b) carrying 
the DOX inducible vector pRTR-c-Kit were treated with DOX for 48 hours 
or left untreated. qPCR was applied to measure the mRNA expression of 
the EMT markers Vimentin, CDH1 and the primary miR-34a transcript. 
Each bar represents the mean +/- SD (n=3). 
 
   This is worth mentioning, since former publications linked c-Kit with EMT 
(Peparini et al, 2009). This assumption was further supported by the finding 
that two crucial EMT-TFs, namely Snail and Slug, induce a stemness gene 
signature and increase the numbers of CD44+/CD117+ cells (Kurrey et al, 
2009). However, according to our data, no mRNAs of EMT-specific-markers, 
such as CDH1 or Vimentin, were regulated by ectopic c-Kit expression.  
 
5.3.4) miR-34a enhances the response of cancer cells to 5-fluorouracil 
by down-regulation of c-Kit 
 
   Recently, c-Kit was shown to mediate chemoresistance in ovarian tumor 
initiating cells (Chau et al, 2012). Therefore, we asked whether c-Kit might 
play a similar role in colorectal cancer. To address this issue DLD1 cells, 
expressing relatively high basal levels of c-Kit, and SW480 cells, expressing 
relatively low basal levels, were employed (Figure 41a). Both cell lines were 
treated either with 5-fluorouracil (5-FU) [20 µg/ml], Doxorubicin 
(=Adriamycin) [0.25 µg/ml] or left untreated for 48 hours. Subsequently, 
apoptosis and cell cycle distribution was determined by DNA content analysis 
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using flow cytometry. SW480 cells, which express lower basal c-Kit levels 
than the respective DLD1 counterparts, showed a much stronger response to 
both chemotherapeutics (Figure 41b). Apoptosis, as indicated by cells in the 
sub-G1 phase, was elevated about 3-fold after treatment with the anti-
metabolite 5-FU and about 4-fold using the anthracycline antibiotic 
Doxorubicin compared to DLD1 cells. Noteworthy, the apoptosis rates of 
untreated cells were increased in SW480 cells as well, compared to DLD1 
cells. 
 
 
 
Figure 41: High levels of c-Kit are associated with a decreased 
apoptotic response to chemotherapy treatment. a) Western blot 
analysis of parental DLD1 and SW480 colorectal cancer cells compar ing 
endogenous c-Kit levels. -tubulin served as loading control. b) Cells 
characterized in a) were treated with either 5-FU or Doxorubicin for 48 
hours or left untreated. Results represent the mean +/ - SD (n=3) for each 
cell line and treatment.   
 
   To prove whether this low chemosensitivity can be influenced by miR-34a, 
DLD1 cells were either transfected with miR-34a or control oligos for 24 hours 
to achieve c-Kit down-regulation. Subsequently, the cells were treated with 
either 5-FU [20 µg/ml] or left untreated and the cell index was measured every 
hour over two days using the xCELLigence real-time cell analyzer (RTCA). 
This revealed an additive effect of miR-34a and 5-FU on DLD1 cells (Figure 
42a): while cells transfected with the control oligo appeared unaffected, 
transfection with miR-34a resulted in a lower cell index over time. Treatment 
with 5-FU negatively influenced the survival of the cells comparably stronger 
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but the most significant response resulted from additive treatment with miR-
34a and 5-FU at the same time.  
   As demonstrated by Western blot analysis in Figure 42b, transfection of 
DLD1 cells with miR-34a resulted in a decrease of c-Kit protein levels. The 
control oligo did not influence the c-Kit protein.  
 
 
 
Figure 42: Ectopic expression of miR-34a enhances response of cancer cells 
to 5-FU by down-regulation of c-Kit. a) DLD1 cells were seeded into wells of 
an E-plate 16 and either transfected with miR-34a or control oligos. 
Thereafter, the cells were treated with either 5-FU or left untreated and 
the cell index was measured using the xCELLigence RTCA. b) Cells 
treated as described in a) were lysed to validate miR-34a-mediated c-Kit 
regulation. The indicated proteins were detected by Western blot 
analysis.  -tubulin served as loading control.  
 
5.3.5) miR-34a inhibits SCF-induced migration and invasion in Colo320 
colorectal cancer cells 
 
   Another function of the SCF/c-Kit axis is an enhancement of migration, 
which was previously observed after treatment of the CRC cell line Colo320 
using SCF (Yasuda et al, 2007). Based on this report it was analyzed whether 
transfection with miR-34a may interfere with the effects of SCF. First, 
regulation of c-Kit by miR-34a was confirmed on mRNA and protein level to 
prove, that c-Kit regulation by miR-34a also occurs in this cellular background 
(Figure 43a/b). As expected, transfection of Colo320 cells with miR-34a 
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oligonucleotides for 48 hours led to a decrease of c-Kit on the mRNA and 
protein levels. 
 
 
Figure 43: Treatment of Colo320 colorectal cancer cells with miR-34a 
oligonucleotides reduces c-Kit mRNA and protein levels.  a) Colo320 
cells were transfected either with a control oligo (ctrl) or miR-34a [50 nM 
each]. qPCR analysis was used to study c-Kit mRNA levels, -actin mRNA 
served as normalization. Results represent the mean +/ - SD (n=3) and 
significance was calculated applying a Student’s t -test. * indicates a p-
values ≤ 0.05. b) Protein lysates of cells treated as described in a) were 
subjected to Western blot analysis in order to compare c-Kit protein levels 
of transfected cells. -tubulin served as loading control.  
  
   Our results confirmed that miR-34a interferes with the expression of c-Kit in 
Colo320 cells and therefore potentially affects SCF-mediated signaling and 
cellular down-stream effects.  
   In order to analyze the migratory behavior, Colo320 cells were transfected 
with either miR-34a or a control oligo [100 nM each] and treated with SCF [10 
ng/ml] or water. After 24 hours cells were seeded into Boyden chambers 
either coated (invasion) or uncoated (migration) with Matrigel. Media were 
supplemented with SCF for stimulated cases. Cells were allowed to migrate 
for 48 hours and pictures of DAPI stained cells (see methods) were taken. As 
shown in Figure 44, transfection of the cells with miR-34a reduced migration 
and invasion compared to the control oligo. In accordance to the previous 
study mentioned above, administration of SCF and control oligo resulted in a 
two to three-fold increase of the migration in both assays. Strikingly, 
administration of SCF and concomitant transfection with miR-34a reduced 
migration and invasion of the cells almost to basal levels. These data suggest 
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that miR-34a interferes with SCF signaling by depletion of the receptor and 
thereby makes the cells refractory to SCF.   
 
 
 
Figure 44: miR-34a transfection abolishes increased cell mobility of 
Colo320 cells upon stimulation with SCF. Colo320 cells were treated 
with and without SCF and transfected at the same time for 24 hours with 
the indicated oligonucleotides. Thereafter cells were seeded into Boyden 
chambers and allowed to migrate for two days to study migration and 
invasion. Migration results are given in a) results of invasion assay are 
given in b). Each bar represents the mean +/- SD (n=3) and significance 
was calculated applying a Student’s t -test. p-values ≤ 0.05 are indicated 
by *. 
 
   An SCF-dependent increase of proliferation rates in Colo320 cells, as 
described by Yusada and colleagues, was not detected and therefore no 
experiments related to proliferation were performed.  
   Since SCF is involved in the regulation of hematopoietic stem cells and 
recent studies indicated a role for c-Kit in stemness in ovarian cancer, the role 
of c-Kit in the regulation of stemness markers was investigated in colorectal 
cancer cells (Kent et al, 2008; Chau et al, 2012). Therefore, c-Kit was 
ectopically expressed in DLD1 cells and changes in mRNA expression of 
several stemness markers were determined by qPCR. As positive control for 
c-Kit-mediated gene regulation, the expression of its downstream effectors c-
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Fos and Oncostatin M, was analyzed (Hoermann et al, 2011; Lennartsson et 
al, 1999). As markers for CRC stemness the following genes were chosen: 
CD44, CD133, Lgr5, Nanog, Nanog P8, β-catenin, Sox2, BMI-1 and OLFM4 
(Horst et al, 2012; Kemper et al, 2010; Ma et al, 2012; Wellner et al, 2009; 
Zhang et al, 2012). c-Fos and Oncostatin M were significantly induced after 
48 hours of c-Kit activation by the addition of DOX (Figure 45). While CD44 
was repressed and BMI-1 expression remained unchanged, all other analyzed 
stemness markers were significantly up-regulated by ectopic c-Kit. These data 
supported the assumption that c-Kit plays a role in colorectal cancer stem 
cells. 
 
 
Figure 45: c-Kit expression induces expression of stemness CRC 
cells. DLD1/pRTR-c-Kit cells were treated with DOX for 48 hours. 
Expression levels of different mRNAs were measured via qPCR. Results 
represent the mean +/- SD (n=3). * indicates a p-value of ≤ 0.05, 
calculated using a Student’s t-test. 
 
   To determine whether an association between c-Kit and stemness markers 
is also found in clinical samples as well, expression data of 196 colorectal 
tumors from the public database TCGA (the cancer genome atlas; Muzny, 
2012) was analyzed (Figure 46). Within this collection, the expression of 
OLFM4, CD44, β-catenin, BMI-1 and Lgr5 mRNA emerged as significantly 
associated with elevated c-Kit mRNA expression (p ≤ 0.05). Additionally, 
elevated SCF mRNA expression correlated with increased expression of its 
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receptor. This supports the assumption that an auto-regulatory loop exists 
between receptor and ligand (Bellone et al, 2006; Hibi et al, 1991; Martinho et 
al, 2008; Theou-Anton et al, 2006). Taken together, these data suggest that c-
Kit plays a role in the regulation of stem cell markers in human colorectal 
tumors as well as in colorectal cancer cell lines. Therefore, the regulation of c-
Kit by miR-34 might be relevant for suppressing colorectal cancer stem cells.    
.    
  
 
 
Figure 46: high c-Kit expression is associated with elevated 
expression of stemness marker mRNA in CRC patients. mRNA 
expression data derived from primary CRC samples (n=196) were 
obtained from the public database TCGA (Muzny, 2012). Correlation 
coefficients and p-values were calculated applying the Spearman 
correlation algorithm. Scatter plots show the respective correlations. 
Both, the c-Kit levels on the x-axes and the y-axes corresponding to 
OLFM4, CD44, Lgr5 and SCF are provided as log10 scale. 
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   To investigate whether miR-34a-dependent regulation of c-Kit might 
interfere with stemness markers in CRC cell lines, the same mRNA 
expression levels were analyzed in previously described DLD1 cells carrying 
a pRTR/pri-miR-34a vector. Upon induction of ectopic miR-34a expression, 
the mRNA levels of c-Kit and the published down-stream effectors c-Fos and 
Oncostatin M were strongly diminished (Figure 47). However, the stemness 
marker mRNAs showed only weak down-regulation compared to the un-
induced state. Most significant changes occurred in the expression of CD44 
and BMI-1. 
 
 
 
Figure 47: Ectopic miR-34a expression down-regulates stemness 
marker genes in CRC cells. DLD1 cells carrying the pRTR/pri-miR-34a 
vector were treated with DOX for 48 hours. Expression of the indicated 
mRNAs was analyzed by qPCR. Results represent the mean +/- SD (n=3). 
* indicates a p-value of ≤ 0.05. 
 
   To determine whether these regulations are functionally relevant for 
stemness, DLD1 cells were subjected to a sphere formation assay, in which 
cells are kept in suspension under non-adherent conditions.  
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Figure 48: miR-34 interferes with SCF-induced sphere formation in 
CRC cells. DLD1 cells were transfected with the indicated 
oligonucleotides, treated with SCF (or water) and subjected to a sphere 
formation assay. Sphere numbers were determined after seven days for 
the first generation (G1) and after additional seven days for G2. 
Treatment with oligonucleotides and SCF was repeated when cells were 
passaged. Results represent the mean +/- SD (n=3) and significance was 
calculated applying a Student’s t -test. * indicates a p-value of ≤ 0.05. G1: 
first generation, G2: second generation 
 
   This assay is widely used to assess self-renewing capacities in cancer stem 
cells. In line with previous publications (Bellone et al, 1997), treatment with 
SCF significantly stimulated sphere formation of DLD1 cells (Figure 48). The 
treatment with ectopic miR-34a oligos reduced the number of resulting 
spheres and moreover reduced sphere formation in presence of SCF to 
baseline levels. These effects were stable over two consecutive generations. 
Representative pictures of the spheres are shown in Figure 49.  
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Figure 49: miR-34 interferes with SCF-induced sphere formation in 
CRC cells. DLD1 cells were treated like described in Figure 48.  
Representative pictures of DLD1 derived G1 spheres, magnification: 40-
fold. 
 
   These results indicate that miR-34 negatively affects the sphere formation 
abilities of colorectal cancer cells by targeting c-Kit. Taken together the results 
show that repression of c-Kit by p53 is mediated via miR-34a. This in turn 
leads to suppression of mitogenic Erk signaling, chemoresistance, 
migration/invasion and stemness. Thereby, and presumably via additional 
effector mechanisms, the p53/miR-34a axis may contribute to tumor 
suppression.  
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6) Discussion 
6.1) miR-34a in EMT 
 
   In the first part of this thesis a double-negative feedback loop between miR-
34 and Snail was identified. In the following section the results and their 
respective consequences for the understanding of EMT regulation are 
discussed.   
 
6.1.1) miR-34a mediates p53-mediated suppression of EMT and 
stemness via Snail 
 
   During this study, the role of miR-34 as an important mediator of p53-
mediated tumor suppression was further substantiated: the direct regulation of 
the EMT-TF Snail by miR-34a was characterized in detail. The down-
regulation of Snail led to a reduction of mesenchymal traits in terms of 
migratory capacities as well as reduction of stemness markers, thereby 
leading to suppression of EMT and induction of MET. These effects underline 
the role of miR-34 as the ‘extended arm of p53’, as it was already shown 
before to induce apoptosis and senescence (reviewed in Hermeking, 2012). 
By employing miR-34 as a down-stream effector, p53 regulates several 
additional targets. This in turn influences different pathways and cellular 
properties. For instance, migration and invasion of CRC cells was heavily 
diminished by p53 in a miR-34-dependent manner. Moreover, the results 
show that miR-34 down-regulates the expression of stemness markers like 
BMI-1, c-Myc, CD44, CD133 and c-Kit, which is particularly discussed in 
section 6.3.2. Some of the miR-34-targeted markers were published before (c-
Myc, CD44), others are novel (c-Kit) and additional ones probably represent 
indirect targets (BMI-1).  
   However, the repression of Snail might also lead to a decrease of stemness 
related genes, since elevated Snail has been implicated in stemness induction 
previously: in immortalized mammary epithelial cells, for instance, the 
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formation of mammospheres, a property associated with mammary epithelial 
stem cells, was elevated by increased Snail expression (Mani et al, 2008). In 
addition, colorectal cancer derived colonospheres displayed high expression 
of Snail and its ectopic expression promoted the formation of colonospheres 
from colorectal cancer cell lines (Hwang et al, 2011b). Furthermore, Snail is 
expressed in the nuclei of crypt base columnar stem cells in the small 
intestine in mice and loss of APC resulted in increased expression of Snail in 
polyps of MIN mice (Horvay et al, 2011).  
   A recent study identified Notch1 mRNA as direct target of miR-34a in colon 
cancer stem cells (Bu et al, 2013). The authors reported that down-regulation 
of Notch by miR-34 led to diminished colonosphere formation and 
tumorigenicity. This supports the results of this thesis, which show that miR-
34 is involved in stemness and sphere formation by down-regulation of Snail 
and c-Kit. Therefore, multiple miR-34 targets potentially contribute to the 
suppression of stemness, presumably in a cell-type dependent manner.  
   This was also found in another study, which shows that in mouse embryonic 
fibroblasts derived from miR-34a deficient mice induced pluripotent stem cell 
(iPSC) generation was elevated compared to wild-type mice (Choi et al, 
2011). The suppression of somatic reprogramming by miR-34a was due, at 
least in part, to repression of several pluripotency genes, including Nanog, 
Sox2 and N-Myc. miR-34b/c similarly repressed reprogramming and all three 
miR-34 members acted cooperatively in this process. This study is 
presumably cancer-relevant as well, since induced pluripotency and 
oncogenic transformation were recently found to be similar, interrelated 
processes (Riggs et al, 2013; Suva et al, 2013). 
   The down-regulation of BMI-1 by miR-34 might occur in an indirect manner, 
since BMI-1 and KLF4 have been characterized as miR-200 targets, which 
might be induced after miR-34-mediated repression of Snail (Wellner et al, 
2009). Besides the miR-34-mediated down-regulation of Snail itself, further 
indirect inhibition of Snail functions may be mediated by the down-regulation 
of the miR-34 target HDAC1 (Kaller et al, 2011; Zhao et al, 2013). Since it 
was shown to be an important co-repressor of Snail, loss of HDAC1 might 
negatively affect Snail-mediated gene regulations (Peinado et al, 2004).  
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   All together the data presented here demonstrate that miR-34 is mediating a 
decrease of stemness and other cellular properties like migration and invasion 
upon induction of p53. Therefore one could describe its role as ‘the extended 
arm of p53’, since it exerts many additional functions, which all result in a 
thorough cancer opposing function, once it is activated by p53.  
 
6.1.2) The transition between epithelial and mesenchymal states is 
controlled by several double-negative feedback loops  
 
   The miR-34-dependent regulation of Snail adds another layer of complexity 
to the regulation of MET by p53, since another analogous feedback loop 
between a p53 induced miRNA and an important EMT-TF was described by 
others before (Brabletz & Brabletz, 2010; Chang et al, 2011; Shimono et al, 
2009): the miR-200 family was shown to target transcription factors of the 
ZEB family, which in turn down-regulate the expression of the miR-200 genes 
and thereby form a bi-stable, double-negative feedback loop, which might be 
important for the cellular plasticity of cancer cells. Several studies have shown 
that a shift towards elevated miR-200 expression concomitantly promotes a 
shift to an epithelial phenotype (Shimono et al, 2009; Wellner et al, 2009). 
Thus, the miRNAs of the miR-200 and the miR-34 family seem to maintain 
and stabilize an epithelial state, while the EMT-TFs antagonize this by 
promoting mesenchymal traits (Brabletz, 2012a).  
   The depicted model (Figure 50) gives a simplified overview of the findings 
made in this sub-project combined with recent publications and emphasizes 
the interplay between molecules determining epithelial and mesenchymal 
states and stemness. Once this equilibrium is out of balance, e.g. by hyper-
methylation of the miRNA promoters or by constitutive activation of the 
transcription factors, and a critical threshold is reached, the EMT-regulators 
can endow tumor initiating cells not only with an increased invasiveness, but 
also with stemness and resistance to apoptosis (Mani et al, 2008; Thiery et al, 
2009). These findings suggest that the two loops have evolved as amplifiers 
of p53-mediated MET and differentiation by controlling several important 
EMT-TFs in parallel. These parallel circuits represent a safety mechanism, 
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which might be important for tumor suppression in case one of the loops is 
inactivated during tumor initiation or progression. According to this model, loss 
of p53, however, seems to be fatal with regards to EMT. Both loops would be 
affected and shifted to the mesenchymal state at the same time by a strong 
induction of Snail and the ZEB family. The presence of intact p53 therefore is 
crucial for the prevention of EMT.  
 
 
Figure 50: Two reciprocal feedback loops control cellular plasticity. 
Certain extracellular stimuli , such as TGF- stimulate expression of EMT 
activators, which induce EMT, stemness and survival  (dark blue). The 
EMT-TFs ZEB and Snail (grey) are linked in double-negative feedback 
loops to the miR-200 and miR-34 families (light blue), respectively. p53 
(black) activates the expression of both miRNA families, thereby shifting 
the feedback loops towards MET (dark blue), epithelial differentiation and 
apoptosis. The close interconnections between miR-200 and miR-34 
genes via co-regulated, common repressors may stabilize the 
transcriptional programs in place in either epithelial or mesenchymal 
cells. Thereby, the immediate response to minor signals and aberrant 
cellular reactions may be suppressed.  
 
   Moreover, the involvement of two or potentially more almost identically 
organized loops is presumably no coincidence. Interestingly, a similar loop-
like mechanism, involving the miRNA let-7, was recently discovered to serve 
as a bi-stable switch in embryonic stem cells and guards the decision 
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between pluripotency and differentiation (reviewed in Gunaratne, 2009). 
These data suggest that the loop-like organized regulation of genes involving 
miRNA activity is a recurring mechanism to control the transitions between 
alternative cellular states. 
   In the context of this study, the role of other important EMT-TFs, besides 
Snail and ZEB, remained unclear. Among the prototypical EMT regulators 
Snail seems to be the only factor, which is directly targeted by miR-34. 
Nevertheless other factors like ZEB1, ZEB2 and Slug might be indirectly 
regulated by miR-34, since they are miR-200 targets and the loss of Snail 
occupancy at the miR-200 promoters might lead to a de-repression of these 
miRNAs. This in turn would result in a down-regulation of their respective 
targets. This is supported by findings in pancreatic acinar cells from mice with 
a deletion of p53, which therefore presumably express low levels of miR-34 
and miR-200 members: Snail, Slug, Twist and ZEB1/2 and several stemness 
markers are highly expressed in these cells, which undergo EMT upon 
subculture and show enhanced sphere formation (Pinho et al, 2011).    
Due to the similarity of the DNA-binding motifs of Snail and Slug it is likely that 
Slug also regulates the expression of miR-34a/b/c. Noteworthy, Slug 
expression is significantly associated with distant metastases in CRC and had 
a significant impact on patient overall survival (Shioiri et al, 2006). This is at 
least similar to what was found for Snail in the present study and suggests an 
analogous role for Slug in CRC. 
 
6.2) Role and potential clinical application of miR-34a in metastatic 
colorectal cancer 
 
    In the second part of this thesis the role of miR-34 and its targets in 
metastatic colon cancer was investigated. The following section contains a 
discussion of the results that were obtained and their potential clinical 
implications in the future. 
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6.2.1) miR-34 silencing and expression are independent of the p53 
status in metastatic colorectal cancer specimen   
 
   The present study revealed a strong correlation of miR-34 promoter-
methylation in primary colon cancer with metastatic spread to the liver, 
whereas miR-34b/c seems to be methylated at high frequencies, irrespective 
of tumor stage or outcome. The data confirm previous findings, which indicate 
that methylation-mediated gene silencing is involved in the progression from 
local colorectal tumors towards metastatic disease (Li & Chen, 2011). Since 
the miR-34 family can be induced by p53, mutation of p53 would presumably 
cause a down-regulation or inability to induce miR-34a. Therefore, one would 
assume that miR-34a methylation would only be advantageous for tumors 
with an intact p53 pathway. This mutual exclusiveness was shown in a 
previous study (Vogt et al, 2011). Contrary to these data, the miR-34 
inactivation was independent of the p53 expression pattern in the present 
study. The differences in cohort composition and location might partially 
explain the contradictory results: in this study, tumors from the right-sided 
colon were analyzed, whereas the previous study included mainly left-sided 
colorectal cancer. Another possible explanation might be that promoter 
methylation occurs early in tumor development and therefore is an 
independent event that precedes p53 inactivation, which occurs relatively late 
during tumorigenesis (Fearon & Vogelstein, 1990; Feinberg et al, 2006). 
Interestingly, there were indications for p53-independent miR-34 regulations 
before, like shown for MK5, which activates miR-34b/c expression via 
phosphorylation of FOXO3a, thereby enabling it to arrest proliferation (Kress 
et al, 2011). Another study showed that p63 can directly bind to p53-
consensus sites in both miR-34a and miR-34c regulatory regions and 
inhibited their activity (Antonini et al, 2010). Moreover, it was shown, that 
ELK1 can up-regulate miR-34a expression as a consequence of BRAF 
induced senescence (Christoffersen et al, 2010). In accordance with this 
study, significantly elevated miR-34a levels were observed in tumors carrying 
the activating BRAF mutation V600E in this study. This and potentially more 
Discussion 
 
103 
 
so far unknown mechanisms might explain the independence of miR-34 
inactivation and expression of the p53 status. 
   Interestingly, decreased levels of miR-34a expression correlate with relapse 
of non–small cell lung cancer, as well as recurrence of breast cancer and poor 
patient survival (Gallardo et al, 2009; Peurala et al, 2011). Therefore, it is 
likely that CpG-methylation of miR-34a in colon cancer is also associated with 
shorter survival and recurrence, presumably due to the associated increase of 
distant metastases detected here. However, our analysis was based on a 
case–control design, using the presence or absence of distant metastases 
within a follow-up period of five years after surgical resection of the primary 
tumor as endpoint. Therefore, the chosen patients do not represent a 
population-based clinical collective. The analyzed markers and marker 
combinations could not be correlated with the overall and disease-free 
survival of the patients. The relevance of the present findings for overall and 
disease-free survival should be the subject of future analyses. 
   Another aspect of this study is an almost ubiquitary methylation of the miR-
34b/c promoter (approximately 92%) in this tumor collection, which does not 
allow any correlation with p53 alterations. Similar frequencies of miR-34b/c 
methylation in colorectal cancer have been previously reported by others: 
90% by Toyota and colleagues, 99% by Vogt and colleagues, and 97.5% by 
Kalimutho and colleagues (Toyota et al, 2008; Vogt et al, 2011; Kalimutho et 
al, 2011). On the contrary, data obtained by Lujambio and colleagues 
contradict these observations (Lujambio et al, 2008): although using the same 
MSP primer sets only about 35% of the colorectal tumor samples from their 
study were positive for miR-34b/c methylation, which was associated with 
metastases formation. Obviously, the extremely high frequency of miR-34b/c 
methylation in the present study of colon cancer cases did not allow any 
association with other parameters. Besides unknown biological mechanisms 
the differences might be explained by technical reasons like sensitivity of the 
MSP assay. 
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6.2.2) Limiting factors for the correlations between the expression of 
miR-34 and its targets  
 
   In contrast to other studies the correlations between low miR-34a and 
elevated target expression was, though being significant, relatively weak. This 
may be due to the fact that miR-34a negatively regulates a variety of targets, 
besides the ones reported herein, each of which has been shown to be 
involved in the promotion of metastases, such as CD44, c-Myc, Axl, TPD52, 
LEF1, or MTA2 (Christoffersen et al, 2010; Kaller et al, 2011; Liu et al, 2011; 
Mudduluru et al, 2011). This multiplicity of potential regulations suggests that 
the entire miR-34-regulated signature of genes is important for the prevention 
of metastases, rather than single targets.  
   Like mentioned before, the expression of the EMT-TF Slug is significantly 
associated with distant metastases in CRC (Shioiri et al, 2006).  Due to the 
similarity of the DNA-binding motifs of Snail and Slug it is likely that Slug also 
regulates the expression of miR-34a/b/c. Therefore, it should be addressed in 
future studies, whether Slug is able to repress of miR-34 genes and whether 
this regulation occurs in CRC, since this would be an alternative mechanism 
for cancer cells to gain a selective advantage besides Snail-mediated 
repression of the miR-34 family. 
   Additionally, all of the miR-34a targets in this study are inter-connected with 
several signaling pathways. Snail, for instance, can be induced by a broad 
spectrum of signaling pathways among them Wnt, TGF-β, Hedgehog, 
EGF/FGF, hypoxia, hepatocyte growth factor (HGF) and NFκB signaling 
(Nieto, 2011; Peinado et al, 2007). All of these possibly influence the 
expression pattern of Snail protein in patient samples and therefore prevent 
detection of potential correlations. The same is true for c-Met and β-catenin, 
which are regulated by different factors as well (Kim et al, 2013; Sadiq & 
Salgia, 2013).  
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6.2.3) Association of miR-34a with other parameters besides metastases 
 
   Though the cohort analyzed here was not designed to address this 
question, we found strong evidence that mature miR-34a levels are 
decreased in N+ compared with N0 tumor samples and the proportion of 
cases showing a methylated miR-34a promoter was significantly higher in 
samples with lymph node metastases. This is supported by a study showing 
that ectopic miR-34a prevents the formation of lymph node metastases in a 
murine model of hepatocellular carcinoma (Guo et al, 2011). Therefore, 
suppression of lymph node metastasis by miR-34a in CRC should be 
addressed in the future. 
   The genome-wide assessment of methylated genes in CRC has revealed a 
unique molecular subgroup of tumors with the so-called CpG island 
methylator phenotype (CIMP). These tumors exhibit a particularly high 
frequency of methylated genes and account for 30% to 40% of right-sided 
colon cancer (Fearon, 2011). In sporadic colon cancer the DNA mismatch 
repair gene hMLH1 is among these methylated genes, which in turn leads to 
high-grade microsatellite instability (MSI-H; Weisenberger et al, 2006). 
Furthermore, CIMP-positive colon cancers usually show either mutation of 
BRAF or KRAS. Our finding that high miR-34a expression, and therefore the 
absence of CpG-methylation at miR-34a promoters, correlates with loss of 
hMLH1 protein expression, MSI-H and the presence of BRAF-mutations, 
indicates that miR-34a is not a "target" of CIMP-associated hyper-methylation. 
This was unexpected, since miR-34a is thought to have tumor suppressive 
activities and represents an important effector of p53 activity. Upon its 
methylation-dependent silencing tumor cells are expected to gain a selective 
advantage.  The silencing of other genes may be more relevant for tumor 
progression in CIMP-positive tumors.  
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6.2.4) Application of miR-34a as diagnostic biomarker 
 
   Since the patient’s prognosis after surgical removal of the primary tumor 
mainly depends on disease recurrence, which is associated with distant 
metastasis, the quest for prognostic markers, which identify patients with high 
risk of recurrence and metastasis, is very important for patient management 
(Mina & Sledge, 2011). The results of the present study indicate that miR-34a 
is preferentially down-regulated via CpG-methylation of its promoter in primary 
colon cancers, which metastasize to the liver. miR-34 silencing was shown to 
be associated with increased expression of several selected miR-34 target 
molecules, which may be part of a larger set of miR-34 targets, which are up-
regulated in tumors. But what might be the clinical consequences and how 
could these findings influence current treatment strategies? The results of this 
study suggest that detection of miR-34a expression and miR-34a CpG-
methylation could be used as a biomarker for metastasizing colorectal tumors, 
which might improve the decisions regarding follow-up treatment of patients 
after resection of primary tumors.  
   Within the last years several prognostic markers have been found to be 
predictive for colorectal cancer outcome and/or distant spread (Neumann et 
al, 2011; Neumann et al, 2012b; Walther et al, 2009; Zlobec & Lugli, 2008). 
Most of them are based on immuno-histochemical detection of certain 
proteins which can be derived from dissected tissue. In contrast, analysis of 
miR-34a methylation and/or expression entails isolation of DNA and/or RNA, 
which would make diagnosis more time and money consuming. However, 
there are arguments, which justify this effort: First, the isolation of nucleic 
acids, either DNA or RNA, offers a much broader insight into the 
genetic/molecular background of the tumor. While tissue sections usually can 
only be stained for one marker at a time, the analysis of nucleic acids 
provides an opportunity to analyze several markers in parallel. In particular, 
several miRNAs have recently been found to be associated with metastatic 
outcome of colorectal cancer (de Krijger et al, 2011). Among these are up-
regulated onco-miRs, such as miR-17-92 and miR-21, as well as down-
regulated tumor suppressing miRNAs like let-7, miR-200b and c. Therefore, 
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the diagnostic detection of expression of a whole panel of miRNAs, including 
miR-34a, is conceivable.  
   Since promoter methylation is a common mechanism of miRNA silencing in 
cancer, the simultaneous analyses of multiple, silenced promoters would be 
beneficial as well. This idea is further supported by recent trials, which 
described the detection of miR-34a CpG-methylation in mucosal wash fluids 
from patients undergoing colonoscopy and isolating DNA from stool samples 
(Kamimae et al, 2011; Ahlquist et al, 2012). This detection of miR-34a 
methylation in released tumor cells could help to determine whether an 
elevated risk for distant metastases of the patients is given. According to our 
theoretical risk assessment, this prognostic value may be further increased by 
the simultaneous analysis of miR-34 targets and might identify sub-groups of 
patients, which should receive an intensified follow-up observation and 
treatment after surgery. This approach is supported by a recent study, which 
analyzed 148 patients with lung adenocarcinomas (Akagi et al, 2013). Here, 
the combined detection of miR-21 expression and a set of four protein coding 
mRNAs was superior to either classifier alone, with regards to the significance 
of the patients prognosis. 
   However, in order to establish miR-34 as a biomarker in the clinic, the 
findings obtained here should be confirmed in further studies using larger 
cohorts of patients. The case-control study design used here allows to draw 
insightful conclusions about the association between factors and the clinical 
condition using a relative small number of investigated cases, but case 
numbers for this study were comparatively low and should be confirmed in 
further studies using larger cohorts of patients. As discussed above, the 
promoters of miR-34b and miR-34c were almost completely silenced by CpG-
methylation. Although this constellation makes detection of methylation 
useless for prognostic purposes regarding distant spread, it may allow early 
detection of colon cancer. For example, it was shown that miR-34b/c 
methylation in stool DNA can be used for early detection of colorectal cancer 
(Kalimutho et al, 2011).  
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6.2.5) Application of miR-34 for therapeutic purposes 
 
   In the present study miR-34a down-regulation was shown to correlate with 
metastases to the liver and the lymph nodes. Besides representing a potential 
diagnostic biomarker, miR-34 recently emerged as a potential therapeutic 
agent to prevent/treat metastases: first results obtained from human cell lines 
in this and previous publications indicate a suppression of cellular migration 
by miR-34 (Yamazaki et al, 2012; Yang et al, 2012b).  
   Moreover, a recent publication demonstrated that miR-34-based therapy 
might be efficient even independent of the p53 status in breast and colorectal 
cancer cell lines (Zhao et al, 2013). The authors report that miR-34-mediated 
repression of HDAC1 leads to an induction of p21CIP1/WAF1, while depletion of 
p21CIP1/WAF1 specifically interfered with the ability of miR-34 to inhibit cancer 
cell proliferation. First, these data suggest that miR-34 controls a tumor 
suppressor pathway previously assigned to p53. Second, the results provide 
an attractive therapeutic strategy for cancer patients irrespective of the p53 
status and third, show an alternative mechanism of miR-34 to mediate growth 
arrest and cellular senescence besides targeting for instance the previously 
described Bcl-2, CDK4, CDK6, Cyclin D1, Cyclin E2 and E2F3 (reviewed in 
Hermeking 2010).  
   These results obtained in cell lines coincide with an anti-cancer effect of 
miR-34 mimetics in several in vivo studies. The ectopic expression of miR-
34a, for instance, was shown to prevent lymph node metastasis in a murine 
model of hepatocellular carcinoma (Guo et al, 2011). This is in accordance 
with the presence of miR-34 methylation and its diminished expression in N+ 
cases, which was found in this study. Moreover, systemic delivery of miR-34a 
was shown to reduce tumor burden and growth of xenografts in mice and led 
to reduced metastases formation. While some researchers used nano 
particles to deliver the synthetic miRNAs (Chen et al, 2010; Pramanik et al, 
2011), others made use of lipid-based vehicles (Trang et al, 2011; Wiggins et 
al, 2010), lentiviral systems (Kasinski & Slack, 2012) or commercial agents, 
such as siPORT and RNALancerII (Liu et al, 2011). Beyond its impact on solid 
tumors miR-34a delivery was shown to abrogate the in vivo growth of large B-
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cell lymphomas (Craig et al, 2012). Taken together, a therapeutic role for miR-
34 in the clinic is more than conceivable, but the emphasis should now be on 
applicability in higher species and man (Bader, 2012; Kasinski & Slack, 2011). 
Recently miR-34 entered a phase 1 trial in patients with primary liver cancer 
or metastatic cancer with liver involvement (Bouchie, 2013). The miR-34 
mimics are delivered using liposomes, which naturally accumulate in the liver, 
making liver cancer the first realistic indication for therapy. Preferential 
targeting of tumor cells is achieved by pH sensitive binding of the liposomes. 
On the basis of the data presented here, miR-34 therapy might prevent the 
formation of metastases in liver and lymph nodes in colorectal cancer 
patients.   
 
 
6.3) miR-34a regulates c-Kit and thereby interferes with several 
cancer relevant processes  
 
   In this study c-Kit was identified as a new target of the miR-34 family. Since 
c-Kit plays a role in numerous cancer-associated pathways, these results 
extend the knowledge of tumor suppressive mechanisms of miR-34.  
   The findings from this sub-chapter are summarized in Figure 51: A variety of 
stresses can result in DNA damage, leading to activation of p53, which in turn 
promotes the transcription of the primary miR-34a transcript. Once the pri-
miRNA is processed, the mature miR-34a can target c-Kit via its 3'-UTR and 
thereby down-regulate the expression of the mature receptor protein. This 
effect mediates several, different responses depending on the cell line/type. 
For instance, miR-34-mediated down-regulation of c-Kit resulted in diminished 
Erk phosphorylation levels, which was associated with decreased anchorage-
independent colony formation in soft agar. Furthermore, low endogenous c-Kit 
protein levels or a decrease of c-Kit expression, caused by ectopic miR-34, 
were associated with increased chemosensitivity. Moreover, miR-34a 
inhibited migration and invasion and also SCF-mediated enhancement of 
these processes in a c-Kit-dependent manner. Finally, activation of c-Kit 
induced several stemness markers in CRC cell lines and was associated with 
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their expression in primary CRC tumors, whereas activation of miR-34a in 
CRC cell lines resulted in a down-regulation of c-Kit and c-Kit-induced 
markers, and suppressed sphere-formation of CRC cells, indicating that CRC 
stemness may be controlled by the miR-34/c-Kit axis.  
   Another group recently reported that miR-34a is able to determine the cell-
fate of early-stage dividing colon cancer stem cells (CCSCs) by degradation 
of Notch1 mRNA (Bu et al, 2013). Elevated miR-34a levels were found in 
differentiating progeny, whereas low levels of miR-34a demarcate self-
renewing CCSCs. Moreover, miR-34a loss of function and gain of function 
altered the balance between self-renewal versus differentiation both in vitro 
and in vivo by generating a sharp threshold response where a bimodal Notch 
signal specifies the choice between self-renewal and differentiation. This is in 
particular interesting, since it is the first evidence for a gradient-dependent 
mechanism that converts noisy input into a toggle switch for robust cell-fate 
decisions. The same principle would for instance be conceivable for the 
regulation of c-Kit, which like Notch1 also represents a trans-membrane 
receptor molecule.  
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Figure 51: The p53/miR-34/c-Kit axis. The model summarizes the 
different effects of miR-34a directly targeting c-Kit in different colorectal 
cancer cells which are presented in this study. Moreover, it links them to 
mechanisms upstream of this cascade (light blue). p53 (black) activity is 
induced upon DNA damage which may be generated by numerous 
factors/stresses, and results in increased miR-34a expression. This in 
turn leads to reduced c-Kit levels by directly targeting the c-Kit 3'-UTR. 
Lowered c-Kit results in multiple effects depicted on the right in dark blue. 
Figure modified from Hermeking, 2007.  
 
6.3.1) The c-Kit/miR-34 axis in cancer 
 
   Our studies were mainly carried out in colorectal cancer cells, which have 
previously been shown to be feasible for studies on c-Kit (Bellone et al, 2001; 
Yasuda et al, 2007). However, the role of c-Kit in CRC is unclear and former 
studies described contradictory results regarding the importance of c-Kit 
expression in CRC: Friedrichs and colleagues found that c-Kit expression is 
rare (17.1%) in colorectal carcinomas, which was in accordance with other 
studies reporting that c-Kit was expressed at very low frequencies in 
colorectal cancer samples (Friederichs et al, 2010; Reed et al, 2002; Yorke et 
al, 2003). Further studies found c-Kit expression in CRC samples in 59% of 
stage II colorectal cancer patients (El-Serafi et al, 2010), in 90% of normal 
colon mucosas and 30% of neoplastic tissue (Sammarco et al, 2004), and in 
15% of primary colorectal tumors and 14% of distant metastases (Preto et al, 
2007).  
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   Though these patient-derived results appear to be very heterogeneous, cell 
culture experiments suggested that c-Kit presumably has a function in 
colorectal cancer cells, since the c-Kit receptor as well as its ligand are 
expressed at elevated levels in colorectal cancer cell lines (Lahm et al, 1995). 
In support of this, Bellone and colleagues demonstrated that SCF was able to 
stimulate anchorage independent growth in four out of five CRC cell lines. 
Besides, the c-Kit receptor staining was found to be over-represented in colon 
cancer tissue compared with normal mucosa from patients. Furthermore, 
aberrant activation of the c-Kit axis was shown to have anti-apoptotic and 
invasion-stimulating effects on DLD1 CRC cells (Bellone et al, 2001; Bellone 
et al, 1997). Moreover, an increased invasion upon addition of SCF was 
documented in Colo320 cells (Yasuda et al, 2007). Our study supports these 
findings and reveals that c-Kit-dependent cancer cell properties can be 
compromised by miR-34: a SCF-mediated increase in the invasive capacities 
of Colo320 cells was found to occur to the same extent in this study as 
reported before. In addition, we found that SCF also increases migration of 
Colo320 cells. Furthermore, this study shows that miR-34a diminishes the 
effects of SCF, presumably by targeting c-Kit, and therefore interrupts the 
SCF signaling pathways, which are responsible for the changes in cell 
behavior.  
   As mentioned above, replacement therapy with miR-34a mimetics was 
successfully tested in several preclinical studies using mouse models of 
cancer and may therefore represent a therapeutic option for the treatment of 
several tumor entities in the future (Guo et al, 2011; Kasinski & Slack, 2011; 
Liu et al, 2011; Pramanik et al, 2011; Wiggins et al, 2010). Our results indicate 
that c-Kit may be up-regulated due to inactivation of miR-34 either by CpG-
methylation or p53 mutations/inhibition. Such tumors may be especially 
sensitive to a replacement of miR-34 using mimetics.   
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6.3.2) Role of c-Kit in stemness, chemoresistance and angiogenesis 
 
   Our results indicate that c-Kit is able to endow cancer cells with properties 
of chemoresistance, which can be partially reverted by miR-34a. This is 
reminiscent of the effect of Imatinib (STI571), which also targets c-Kit and was 
shown to be therapeutically effective against gastrointestinal stromal 
tumors/GISTs (Attoub et al, 2002; van Oosterom et al, 2001). Imatinib 
rendered DLD1 cells, which express high c-Kit levels, more responsive to the 
cytotoxic effect of 5-FU [0.03-1 mM] (Bellone et al, 2004). Therefore, the 
additive effect of c-Kit inhibition and 5-FU has precedence and should be 
studied further, since this potentially allows a dose reduction of 
chemotherapeutic compounds in the future. miR-34 mimetics were previously 
shown to sensitize cell lines derived from other types of tumors, such as 
breast, prostate and lung cancer towards chemotherapy (Fujita et al, 2008; Li 
et al, 2012; Wang et al, 2012) and elevated miR-34a was associated with 
chemosensitivity in patients with gastric cancer (Kim et al, 2011a). Therefore, 
miR-34 mimetics are promising candidates for clinical applications (Bader, 
2012). 
   Furthermore, we found that c-Kit activation results in the up-regulation of 
several stemness markers in colorectal cancer cells and primary tumors. This 
is in accordance with previous findings, which show that colorectal cancer 
stem cells display increased resistance towards chemotherapeutics such as 
5-FU (Bitarte et al, 2011; Hsu et al, 2013). A potential mechanism how c-Kit 
mediates chemoresistance was proposed by Chau and colleagues (Chau et 
al, 2012). In their study c-Kit activation was shown to up-regulate ABCG2 to 
confer chemoresistance in ovarian cancer. This membrane-bound protein is a 
member of the ATP-binding cassette (ABC) transporter super-family. The 
authors report, that this effect was mediated via Phosphatidylinositol-3-kinase 
(PI3K)/Akt signaling and β-catenin/TCF-mediated transcriptional activation of 
ABCG2. They discuss that this is in particular interesting, since this pathway 
was shown to be involved in the regulation of ABC drug transporters before, 
which might explain why stem cells are resistant to a variety of agents, rather 
than towards a single chemotherapeutic agent (Scotto, 2003; Kemper et al, 
Discussion 
 
114 
 
2010). Since β-catenin/TCF signaling is frequently altered in colorectal cancer 
as well, this mechanism might also apply to this entity and should be 
addressed in further studies (Brabletz et al, 2005). The correlation between β-
catenin and c-Kit expression in colorectal tumor samples, shown within this 
study, further supports this assumption.  
   Interestingly, previous publications revealed that miR-221 and 222 regulate 
angiogenic processes via targeting c-Kit (Poliseno et al, 2006). Tumor-
angiogenesis is an important step in tumorigenesis, since solid tumors have to 
be supplied with nutrients from the blood stream to exceed a certain size. 
Since miR-34a targets c-Kit as well, effects of p53 on tumor-angiogenesis 
may be mediated, at least in part, via miR-34. 
 
6.3.3) miR-34a targets multiple receptor tyrosine kinases  
 
   In this study c-Kit was identified and characterized as a new miR-34a target. 
Interestingly, several other studies recently reported other receptor tyrosine 
kinases, which are regulated via miR-34a, among them c-Met, Axl and 
PDGFR (Corney et al, 2010; Mudduluru et al, 2011; Silber et al, 2012). 
Therefore, miR-34 seems to specifically target this class of signaling 
molecules, which are of central importance for cancer, since they regulate 
processes essential for tumor initiation and progression. By suppression of 
RTKs, miR-34 may be able to effectively mediate tumor suppression by p53. 
In the future, additional studies may reveal whether additional RTKs represent 
targets of the miR-34 family. 
 
6.4) Potential relevance for non-cancerous processes 
 
   All of the sub-projects reported in this work addressed the biology or clinical 
applications of miR-34 related to human cancer. Nevertheless, some 
interesting findings emerged during these studies, which might be of 
relevance to other diseases as well. 
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6.4.1) Additional findings from the M0/M1 patient collection 
 
   As discussed above, the patient collection, which was analyzed here, was 
designed to determine factors, which are important for the formation of distant 
metastases in colon cancer. However, the expression of the mature miRNA in 
patients revealed some interesting associations. For instance, the expression 
of the mature miRNA was significantly elevated in tumors of older patients. 
This is consistent with recent studies, which reported elevated mature miR-
34a during aging in rat liver and fruit flies, senescence of human diploid 
fibroblast, as well as during senescence of the eye and cardiac aging in 
humans (Boon et al, 2013; Chien et al, 2013; Li et al, 2011; Liu et al, 2012; 
Maes et al, 2009). Interestingly, a recent publication reported that c-Kit 
positive stem cells are necessary and sufficient for functional cardiac 
regeneration and repair (Ellison et al, 2013). In combination with the results 
obtained in the present study, this suggests that the influence of miR-34a on 
aging might be mediated via inhibition of c-Kit, since down-regulation of c-Kit 
would result in diminished regeneration and therefore enable miR-34 to 
promote aging.  
   However, it remains largely unclear why older patients, which have a higher 
risk for cancer, in general show increased levels of miR-34a, which is 
supposed to be protective against cancer. One plausible explanation is 
increased p53 activity in aged tissues due to accumulation of DNA damage 
caused by e.g. telomere shorting, exogenous DNA damaging insults, such as 
irradiation or endogenous free radicals (Sharpless & DePinho, 2002; 
Vogelstein et al, 2000). However, as other variables also change with age, 
additional processes may lead to an up-regulation of miR-34. 
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6.4.2) The miR-34/c-Kit axis in allergic disorders 
 
   The role of c-Kit as a new miR-34a target was elucidated in this study. Since 
both, miR-34a and c-Kit, share an interface with a multitude of signaling 
pathways, more detailed analyses are necessary in order to illuminate the 
different aspects and consequences, which are inherent in this regulation. For 
instance activation of c-Kit is not only associated with cancer, but seems to 
play a role in allergic asthma as well (Krishnamoorthy et al, 2008). Recently, 
miR-34a was shown to interfere with a component of the mTOR signaling 
pathway and thereby to play a role in mast cell survival – a process critical in 
allergic disorders (Shin et al, 2012). Moreover, TGF-β was reported to 
suppress miR-34 thereby leading to secretion of the chemokine CCL22, which 
is a direct target of miR-34, and recruitment of regulatory T cells (Yang et al, 
2012a). In line with this, miR-34/449 family members were shown to be 
repressed in airway epithelial cells of asthmatic patients compared to healthy 
controls (Solberg et al, 2012). These findings place miR-34 in the context of 
allergic disorders and miR-34-dependent down-regulation of c-Kit might 
therefore be important for these diseases as well. Interestingly, inhibition of 
different RTKs and particularly c-Kit seems to affect asthma via decreasing 
histamine levels, infiltration of mast cells and eosinophils, interleukin (IL)-4 
production and airway hyper-responsiveness in vivo (Guntur & Reinero, 2012; 
Jensen et al, 2007; Reber et al, 2006). Since miR-34a was successfully tested 
as a potential new therapeutic agent in the lung and other organs using 
mouse models, it will be interesting to see, whether miR-34-based therapies 
can also be applied to treat immune dysregulations such as allergic asthma 
(Guo et al, 2011; Kasinski & Slack, 2011; Liu et al, 2011; Pramanik et al, 
2011; Wiggins et al, 2010). 
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7) Summary 
 
   Over the last years miR-34 emerged as a major down-stream effector of the 
tumor suppressor p53. In particular, miR-34 was shown to trigger several 
cancer suppressive processes like apoptosis, cell cycle arrest and 
senescence by targeting the mRNAs of different target genes such as the 
survival factor Bcl-2 or different CDKs.    
   During this study, we could show that the EMT-TF Snail was regulated by 
miR-34. This amplifies the miR-34-mediated tumor suppressive effect by 
stabilizing the epithelial phenotype, and was associated with reduced 
migration and invasion and inhibition of stemness. Furthermore, Snail was 
shown to target miR-34, thereby forming a regulatory feedback loop 
controlling the transition between epithelial and mesenchymal traits, which is 
also important for metastases formation.  
   In further experiments on colorectal cancer tissue samples, miR-34 was 
shown to be significantly repressed in primary tumors, which were associated 
with metastases to the liver within five years after removal. Further analyses 
suggested that this was probably due to epigenetic silencing, since a 
significant proportion of the cases with low miR-34a expression showed a 
CpG-methylation of the miR-34a promoter region. Subsequent 
immunohistochemical analyses of the miR-34a targets Snail, c-Met and -
catenin revealed that detection of miR-34a silencing in resected primary colon 
cancer is of prognostic value for the prediction of distant metastases, 
especially in combination with detection of c-Met and -catenin expression.  
   Additionally, the receptor tyrosine kinase c-Kit was identified as a new miR-
34 target in this study. First results in different cell lines indicate that this 
regulation can have implications for cancer related cell properties like 
sensitivity to chemotherapeutic agents, migration and stemness.  
   Taken together the results obtained in this study improve the understanding 
of miR-34 and support its role as tumor suppressor. Furthermore, the results 
suggest that detection of the loss of miR-34 can be used for diagnostic 
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purposes. In addition, the results are in favor of current activities, which aim to 
bring miR-34 to the clinic as a therapeutic agent.   
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8) Zusammenfassung 
 
   In den vergangenen Jahren zeichnete sich miR-34 als einer der 
Haupteffektoren des Tumorsuppressors p53 ab. Im Einzelnen wurde gezeigt, 
dass miR-34 verschiedene, einer Krebserkrankung vorbeugende Prozesse 
wie Apoptose, Zellzyklus-Arrest und Seneszenz vermittelt, indem sie die 
mRNAs verschiedener Zielgene herunter reguliert, darunter zum Beispiel der 
Überlebensfaktor Bcl-2 oder verschiedene Cyclin-abhängige Kinasen (CDKs).  
   Im Laufe dieser Studie konnten wir zeigen, dass der EMT-induzierende 
Transkriptionsfaktor Snail ebenso von miR-34 reguliert wird. Dadurch 
verstärkt sich der miR-34-vermittelte Tumor-supprimierende Effekt indem der 
epitheliale Phänotyp stabilisiert, zelluläre Migration und Invasion reduziert und 
Stammzelligkeit inhibiert werden. Darüber hinaus wurde gezeigt, dass Snail 
selbst die Expression von miR-34 hemmt, womit es eine regulatorische 
Rückkopplungsschleife bildet, die den Übergang zwischen epithelialen und 
mesenchymalen Eigenschaften einer Zelle kontrolliert, der für die Bildung von 
Metastasen wichtig ist.    
   In weiteren Analysen wurde anhand von kolorektalem Tumorgewebe 
gezeigt, dass miR-34 präferenziell in Primärtumoren reprimiert wurde, die 
innerhalb von fünf Jahren nach ihrer Entfernung mit Lebermetastasen einher 
gingen. Weitere Analysen legten nahe, dass dies wahrscheinlich auf 
epigenetischer Promotor-Inaktivierung beruhte, da ein signifikanter Anteil der 
schwach miR-34 exprimierenden Tumoren eine CpG-Methylierung am miR-
34a Promotor aufwiesen. Weiterführende immunhistochemische Analysen der 
Proteine Snail, c-Met und β-catenin, deren mRNAs Zielstrukturen von miR-
34a sind, ergaben, dass der Nachweis von miR-34a Inaktivierung und 
Zielgen-Expression bei operativ entfernten, kolorektalen Karzinomen von 
prognostischem Wert für die Vorhersage von Fernmetastasen sein kann. Dies 
galt im Speziellen für den Nachweis der Kombination aus miR-34a Promotor 
Hyper-Methylierung und erhöhter Expression von c-Met und β-catenin.  
   Zudem wurde in dieser Studie auch die Rezeptor-Tyrosin-Kinase c-Kit als 
eine neue Zielstruktur von miR-34 identifiziert. Erste Ergebnisse in 
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verschiedenen Zelllinien zeigen, dass diese Regulation auf Krebs-assoziierte 
Zell-Eigenschaften Einfluss nehmen kann. Darunter fallen die Sensitivität 
gegenüber Chemotherapeutika, gesteigerte Migration und Invasion und 
Stammzelligkeit.  
   Zusammengefasst verbessern die Ergebnisse, welche im Laufe der 
vorliegenden Studie erhoben wurden, das Verständnis für die Funktion von 
miR-34 und unterstützen seine Rolle als Tumorsuppressor. Darüber hinaus 
lassen die Ergebnisse vermuten, dass der Nachweis des Verlustes von miR-
34 künftig für diagnostische Zwecke verwendet werden kann. Die Ergebnisse 
unterstützen zudem gegenwärtige Aktivitäten, die darauf abzielen miR-34 als 
Therapeutikum klinisch einzusetzen. 
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9) Publications 
 
The results of this thesis have been published in the following articles: 
 
Original articles: 
 
 Siemens H*, Jackstadt R*, Hünten S*, Kaller M*, Menssen A*, Götz U and 
Hermeking H (2011). miR-34 and SNAIL form a double-negative feedback 
loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10 (24), 4256-
71.  
(IF 2011: 5.359) 
  
 Siemens H*, Neumann J*, Jackstadt R, Mansmann U, Horst D, Kirchner T 
and Hermeking H (2013). Detection of miR-34a promoter methylation in 
combination with elevated expression of c-Met and β-catenin predicts distant 
metastasis of colon cancer. Clinical Cancer Research 19 (3), 710-20.  
(IF 2012: 7.837) 
 
 Siemens H, Jackstadt R, Kaller M and Hermeking H (2013). Repression of c-
Kit by p53 is mediated by miR-34 and is associated with reduced 
chemoresistance, migration and stemness. Oncotarget 4 (9), advance online 
publications 
(IF 2012: 6.636) 
 
Review/book chapter: 
 
 Hünten S*, Siemens H*, Kaller M*, Hermeking H (2013). The p53/microRNA 
network in cancer: experimental and bioinformatics approaches. Advances in 
Experimental Medicine and Biology 2013; 774: 77-101.  
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In addition, I made contributions to the following submitted 
manuscripts, which are not further described here: 
 
Original articles: 
 
 Hahn S, Jackstadt R, Siemens H, Hünten S and Hermeking H (2013). SNAIL 
and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-
mesenchymal-transition. (The EMBO Journal, manuscript under revision) 
 
 Shi L, Jackstadt R, Siemens H, Li H, Kirchner T and Hermeking H (2013). 
p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to 
regulate epithelial-mesenchymal transition and metastasis in colorectal 
cancer. (Cancer Research, manuscript under revision) 
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11) Abbreviations 
 
5-FU 5-fluorouracil 
ABCG2 ATP-binding cassette sub-family G member 2 
Ago argonaute protein 
APS ammonium peroxodisulfate 
Bcl-2 B-cell lymphoma 2 
bp basepairs 
BTG4 B-cell translocation gene 4 
CD cluster of differentiation 
CDC20 cell-division cycle protein 20 
CDK cyclin-dependent kinase 
cDNA complementary DNA 
(q)ChIP  (quantitative) chromatin immunoprecipitation 
CI confidence interval 
c-Kit 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
c-Met/HGFR hepatocyte growth factor receptor 
c-Myc v-MYC avian myelocytomatosis viral oncogene homologue 
CpG cytidine-phosphate-guanidin 
CRC colorectal cancer 
CSC cancer stem cell 
Cy3 cyanine 3 
DAPI 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride 
DMEM Dulbecco`s modified Eagles medium 
DMSO dimethyl-sulfoxide 
DNA deoxyribonucleic acid 
DNMT DNA-methyltransferase 
DOX doxycycline 
E.coli Escherichia coli 
E-box  enhancer box 
ELK1 ETS-like gene 1 
EMT epithelial-mesenchymal transition 
Erk extracellular signal-regulated kinase 
ETS E-twenty six 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
FOXO3 forkhead box O3 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
gDNA genomic DNA 
GFP green fluorescent protein 
GIST gastrointestinal stromal tumor 
HBSS Hanks`balanced salt solution 
Abbreviations 
 
145 
 
HDAC histone deacetylase 
HDF human diploid fibroblast 
HGF hepatocyte growth factor 
HRP horseradish peroxidase 
IF immunofluorescence 
IHC immunohistochemistry 
LEF1 lymphoid enhancer-binding factor 1 
Lgr5 leucine rich repeat containing G protein coupled receptor 5 
MAPK mitogen-activated protein kinase 
MBP methyl-CpG-binding domain protein 
MDM2 mouse double minute 2 homolog 
MEK1/MAP2K1 dual specificity mitogen-activated protein kinase kinase 1 
MET mesenchymal-epithelial transition 
miR(NA) microRNA 
MK5 MAP kinase-activated protein kinase 5 
mRNA messenger RNA 
MSP methylation specific PCR 
MTA2 metastasis-associated protein MTA2 
mTOR mammalian target of rapamycin 
OR odds ratio 
ORF open reading frame 
PARP poly (ADP-ribose) polymerase 
PBS phosphate buffered saline 
(q)PCR (quantitative) polymerase chain reaction 
PDGF platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
PI3K phosphoinositide-3-kinase 
pri-miR(NA) primary microRNA transcript 
Rb retinoblastoma protein 
RFP red fluorescent protein 
RISC RNA induced silencing complex 
RNA ribonucleic acid 
RNAi RNA interference 
RNAPol RNA polymerase 
RT room temperature 
RTK receptor tyrosine kinase  
SATB2 special AT-rich sequence-binding protein 2 
SCF stem cell factor 
SD standard deviation 
SDS sodium dodecyl sulfate 
SBS Snail binding site 
STAT signal transducers and activators of transcription 
TAR  transactivation-responsive 
TCF T cell transcription factor 
Abbreviations 
 
146 
 
Temed tetramethylethylenediamine 
Tet tetracycline 
TF transcription factor 
TRBP (TAR) RNA binding protein 
TSS transcription start site 
tTa tetracycline-controlled transactivator 
U unit 
UTR untranslated region 
VSV vesicular stomatitis virus (tag) 
WB Western blot 
ZEB zinc finger E-box-binding homeobox protein 
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